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and palate, and [3] cleft palate) 
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CLP cleft lip and palate (excludes [1] cleft lip and [2] cleft palate) 
CL/P cleft lip and/or cleft palate = cleft lip + cleft lip and palate + 
cleft palate (no exclusions) 
CLPTM cleft lip and palate transmembrane 
COL Collagen 
CP cleft palate (excludes [1] cleft lip and [2] cleft lip and palate) 
CPO cleft palate only 
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GWA  genome-wide association 
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HEMGN Hemogen 
ICBDSR International Clearinghouse for Birth Defects Surveillance and 
Research 
IPDTOC International Perinatal Database of Typical Orofacial Clefts 
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Kb kilobase, 1.000 base pairs 
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LD linkage disequilibrium 
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M mutation detection 
MAF minor allele frequency 
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MMP matrix metalloproteinase 
MSX muscle segment homeobox 
MTHFR methylenetetrahydrofolate reductase 
MYH myosin, heavy chain 9, non-muscle 
NAT N-acetyltransferase 
NSOC nonsyndromic oral cleft 
OC oral cleft 
OFC orofacial cleft 
OMIM Online Mendelian Inheritance in Man 
OR odds ratio 
P63 tumour protein p63 
PAX paired box  
p.c.wk post-coital week 
PDGFC platelet derived growth factor C 
PHF PHD finger protein 
PLINK whole genome association analysis toolset 
PPS popliteal pterygium syndrome 
PQBP polyglutamine binding protein 
PTCH protein patched homolog 
PVR (L) poliovirus receptor (like) 
RARA retinoic acid receptor, alpha 
RYK receptor-like tyrosine kinase 
SATB SATB homeobox 
SHH sonic hedgehog homolog 
SKI v-ski sarcoma viral oncogene homolog 
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SNP single nucleotide polymorphism 
tag SNP haplotype-tagging SNP 
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UCSC University of California, Santa Cruz 
VAX ventral anterior homeobox  
VWS van der Woude syndrome  






Cleft lip (CL), cleft lip with or without cleft palate (CL/P) and isolated cleft 
palate (CP), collectively termed oral clefts (OC), are the second most common 
birth defects among newborn. These defects arise in about 1 in 700 liveborn 
babies, with ethnic and geographic variation. Approximately 75% of CL/P and 
50% of CP cases are isolated defects and no other deformities are found in those 
children. Those OCs are therefore called nonsyndromic (Stainer and Moore, 
2004). 
Although OC is usually not a life-threatening condition, many functions 
such as feeding, digestion, speech, middle-ear ventilation, and hearing, respi-
ration, facial and dental development can be disturbed because of the structures 
involved. These problems can also cause emotional, psychosocial and edu-
cational difficulties. Affected children need multidisciplinary care from birth 
until adulthood (Mossey et al., 2009). Orofacial clefts pose a burden to the 
individual, the family, and society, with substantial expenditure, and rehabili-
tation is possible with good quality care. Care for children born with these de-
fects generally includes many disciplines – nursing, facial plastic surgery, 
maxillofacial surgery, otolaryngology, speech therapy, audiology, counselling, 
psychology, genetics, orthodontics, and dentistry. Fortunately, early and good 
quality rehabilitation of children with OC usually gives satisfactory outcomes. 
Identification of etiological factors for OC is the first step towards primary 
prevention. Genetic factors contributing to CL/P formation have been identified 
for some syndromic cases, but knowledge about genetic factors that contribute 
to nonsyndromic CL/P is still unclear. The high rates of familial occurrences, 
risk of recurrence, and elevated concordance rates in monozygotic twins pro-
vide evidence for a strong genetic component in nonsyndromic CL/P. However, 
concordance in monozygotic twins ranges between 40% and 60%, which means 
that the exact inheritance pattern of OC is more complex. It has been suggested 
that the development of nonsyndromic OC occurs as a result of the interaction 
between different genetic and environmental factors (Mitchell and Risch, 1992; 
Carinci et al., 2000; Carinci et al., 2003; Carinci et al., 2007). The identification 
of the genes responsible for diseases has been a major focus of human genetics 
over the past 40 years. The introduction of modern molecular methods, experi-
mental animal knockout models and advances in the technique of gene mapping 
have provided new candidate genes for orofacial clefting, both for syndromic 
and nonsyndromic cases. However, the results of earlier candidate-gene-based 
association studies, performed in different populations, have been conflicting, 
with only a few candidate loci being implicated in OC phenotypes. This 
inconsistency indicates the challenges in searching associations with a relatively 
rare phenotype such as nonsyndromic clefting. 
The primary purpose of the present study was to give an overview of OC in 
Estonia. National statistics regarding orofacial clefts in Estonia was non-
existent at the start of this study. The only prevalence findings known to us 
were those of Lõvi-Kalnin (1996), conducted during 1970–1980. On the basis 
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of the data from the study, the current rate of occurrence of clefts in Estonia 
would be 1 case per 777 live births. The only way to estimate the number of 
children affected by clefts is to use the pre-existing information from previous 
visits to maxillofacial surgeons. Genotype-phenotype correlation research in 
this area could yield important information on risk factors. Therefore, our 
second main purpose was to investigate the possible contributions of recognized 
candidate genes, on the basis of multiple reports on the association between 
markers and haplotypes in various genes and orofacial clefts from a previously 
uncharacterized ethnic background of three genetically close populations from 






REVIEW OF LITERATURE 
1. Embryonic development 
The development of the head (Figure 1) involves the interaction of several cell 
populations and the coordination of cell signalling pathways which, when 
disrupted, can cause defects such as facial clefts. Development of the lip and 
palate entails a complex series of events (Table 1). Disturbances at any stage 
during palate development (e.g., defective palatal shelf growth, failed or 





Figure 1. Development of the lip and palate 
a. The developing frontonasal prominence, paired maxillary processes and paired man-
dibular processes surround the primitive oral cavity by the 4th week of embryonic 
development. 
b. By the 5th week, the nasal pits have formed, which leads to the formation of the 
paired medial and lateral nasal processes. 
c. The medial nasal processes have merged with the maxillary processes to form the 
upper lip and primary palate by the end of the 6th week. The lateral nasal processes 
form the nasal alae. Similarly, the mandibular processes fuse to form the lower jaw. 
d. During the 6th week of embryogenesis, the secondary palate develops as bilateral 
outgrowths from the maxillary processes, which grow vertically down the side of the 
tongue. 
e. Subsequently, the palatal shelves elevate to a horizontal position above the tongue, 
contact one another and commence fusion. 
f. Fusion of the palatal shelves ultimately divides the oronasal space into separate oral 











6 14 days Primitive streak appears; oropharyngeal membrane 
forms 
8 17 days Neural plate forms 
9 20 days Cranial neural folds elevate; otic placode appears 
10 21 days Neural crest migration commences; fusion of neural 
folds; otic pits forms 
11 24 days Frontonasal prominence swells; first arch forms; wide 
stomodeum; optic vesicles form; anterior neuropore 
closes; olfactory placode appears 
12 26 days Second arch forms; maxillary prominence appear; lens 
placodes commence; posterior neuropore closes; adeno-
hypophysial pouch appears 
13 28 days Third arch forms; dental lamina appears; fourth arch 
forms; oropharyngeal membrane ruptures 
14 32 days Otic and lens vesicles present; lateral nasal prominence 
appear 
15 33 days Medial nasal prominence appear; nasal pits form-
widely separated, face laterally 
16 37 days Nasal pits face ventrally; upper lip forms on lateral as-
pect of stomodeum; lower lip fuses in midline; retinal 
pigment forms; nasolacrimal groove appears, demar-
cating nose; neurohypophysial evagination 
17 41 days Contact between medial nasal and maxillary pro-
minence, separating nasal pit from stomodeum; upper 
lip continuity first established; vomeronasal organ 
appears 
18 44 days Primary palate anlagen project posteriorly into stomo-
deum; distinct tip of nose develops; eyelid fold form; 
retinal pigment; nasal pits move medially; nasal alae 
and septum present; mylohyoid, geniohyoid and genio-
glossus muscle form 
19 47–48 days Nasal fin disintegrates; (failure of disintegration pre-
disposes to cleft lip); the rima oris of the mouth di-
minishes in width; mandibular ossification commences 
20 50–51 days The lidless eyes migrate medially; nasal pits approach 
each other; ear hillocks fuse 
22 54 days The eyelids thicken and encroach upon the eyes; the 
auricle forms and projects; the nostrils are in definite 
position 
23 56–57 days Eyes are still wide apart but eyelid closure commences; 
nose tip elevates; face assumes a human fetal appea-
rance; head elevates off the thorax; mouth opens; pala-
tal shelves elevate; maxillary ossification commences 
Fetus 60 days Palatal shelves fuse; deciduous tooth buds form; 
embryo now termed a fetus 
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1.1. Lip development 
During the third week of gestation, neural crest cells proliferate and migrate 
into the frontonasal and visceral arch region to form the five facial primordia. 
By the post-coital fourth week (p.c.4wk), five primordia (consisting of the 
frontonasal prominence, the paired maxillary prominences, and the paired 
mandibular prominences) surround the primitive oral cavity. The frontonasal 
prominence forms the forehead and the nose. The maxillary prominences are 
bilateral and form the lateral stomodeum (primitive mouth). The mandibular 
prominences are also bilateral and are responsible for the caudal growth of the 
stomodeum. The neural crest cells within these prominences differentiate into 
skeletal and connective tissue of the face, bone, cartilage, fibrous connective 
tissue, and all dental tissues except enamel (Sperber, 2010). During the fourth 
week (p.c.4wk), the medial ends of the mandibular prominences merge to form 
the mandible, lower lip, and lower cheek region. Toward the end of the fourth 
week, nasal placodes form on the lower aspect of the frontonasal prominence. 
The nasal or olfactory pits form and extend into the primitive mouth, and these 
become the nostrils. Rapid growth continues in weeks five to six (p.c.5–6wk). 
In weeks six to seven (p.c.6–7wk), rapid proliferation of the maxillary pro-
minences results in the medial nasal prominences merging with each other and 
the lateral nasal prominences to form the lateral nose and cheek regions. The 
upper lip is formed during this period by the lateral movement of the maxillary 




1.2. Palate development 
Palate development begins during the post-coital fifth week (p.c.5wk), after 
fusion of the upper lip, and is complete at the end of the twelfth week. Palatal 
development follows up the initial development of the oral region with further 
proliferation and migration of the maxillary prominences. Development of the 
palate is divided into two regions: the primary and secondary palate. Develop-
ment of the primary palate starts with further development of the intermaxillary 
segment of the maxilla. This tissue is derived from the maxillary prominences 
merging with the medial nasal prominences. The intermaxillary segments of the 
maxilla form the labial components that form the philtrum of the upper lip and 
the bony palatal component. The primary palate extends posteriorly to the 
incisive foramen, located immediately behind the alveolar ridge (Moore and 
Persaud, 2008). 
The secondary palate originates as an outgrowth of the maxillary promi-
nences (p.c.6wk). During the seventh week of development, the palatal shelves 
rise to a horizontal position above the tongue, and come into contact and fuse to 
form a midline epithelial seam, which subsequently degenerates to allow 
mesenchymal continuity across the palate. The palatal mesenchyme then diffe-
rentiates into bony and muscular elements that correlate with the position of the 
17 
 
hard and soft palate respectively. With continued growth, the shelves appose at 
the midline (p.c.10wk) and eventually fuse (p.c.13wk) (Murray and Schutte, 
2004). 





Figure 2. Gene expression during different stages of palatal development  
The schematic drawing shows coronal view of normal palate shelf and key stages of 
palatal development. Main genes that express and function at each palatal develop-
mental stages are summarized. Genes are separated according to the location of its 
expression pattern (mesenchyme vs. epithelium) (Wenli Yu et al., 2009).  
1: Blavier L. et al, 2001, Mol Biol Cell; 2: Braybrook C. et al, 2002, Hum Mol Genet; 3: 
Britto JA. et al, 2001, Cleft Palate Craniofac J; 4: Brown NL. et al, 2002, J Dent Res; 5: Cho 
KW. et al, 2008, Gene Expr Pattern; 6: Cui XM et al, 1998, Int J Dev Biol; 7: Cui XM. et al, 
2000, Int J Dev Biol; 8: Cui SM. et al, 2003, Dev Biol; 9: Dean D. et al, 2008, Development; 
10: McLean W. et al, 2008, Mech Dev; 11: FitzPatrick DR. et al, 2003, Hum Mol Genet; 12: 
Gato A. et al. 2002. Dev Biol; 13: Hagiwara N. et al, 2003, Dev Biol; 14: He F. et al, 2008, 
Development; 15: Kondo S. et al, 2002, Nat Genet; 16: Lan Y, et al, 2004, Development; 
17: Lee J-M. et al, 2008, Dev Biol; 18: Li Q. et al, 2007, Int J Dev Biol; 19: Martínez-
Álvarez C. et al, 2004, Dev Biol; 20: Nie XG. et al, 2006, Int J Dev Biol; 21: Pelton RW. et 
al, 1990, Dev Biol; 22: Rice R. et al, 2004, J Clin Invest; 23: Rice R. et al, 2005, Dev Dyn; 
24: Rice R. et al, 2006, Gene Expr Patterns; 25: Xu X. et al, 2005, Dev Dyn; 26:Yu L., et al, 
2005 Development; 27: Yu W. et al, 2008, Dev Dyn; 28: Zhao YG. et al, 1999, PNAS; 29: 
Zoupa M., 2006, Int J Dev Biol. 
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Mice and chicks have played a central part in dissection of the molecular path-
ways underlying development of the lip and palate. In both species, develop-




2. Classification of clefts 
Various classification schemes for OC have been devised in the last 70 years, 
but few have received widespread clinical acceptance. OC can be classified on 
the basis of etiology and/or pathogenesis. There have been multiple classifi-
cations of OC based on anatomic and embryological considerations.  
 
 
2.1. Fogh-Andersen classification (1942)  
Fogh-Andersen divided OC as follows: 
CL extending to the incisive foramen, including clefts of the alveolus 
CL and CP (CLP), including unilateral and bilateral CLP 
CP identified as being median and not extending beyond the incisive foramen. 
 
 
2.2. Davis and Ritchie classification (Davis and Ritchie, 1922) 
The Davis and Ritchie classification divides CL/P into two groups, which are 
subdivided by the extent of the cleft (eg, 1/3, 1/2), as follows:  
Group I –  Clefts anterior to the alveolus (unilateral, median, or bilateral 
cleft lip). 
Group II –  Postalveolar clefts (cleft palate alone, soft palate alone, soft 
palate and hard palate, or submucous cleft). 
 
 
2.3. Veau classification (Figure 3) 
Group I –  Defects of the soft palate only. 
Group II –  Defects involving the hard palate and soft palate. 
Group III –  Defects involving the soft palate to the alveolus, usually in-
volving the lip. 






Figure 3. Veau classification 
A: Group I. Defects of the soft palate only. B: Group II. Defects involving the hard 
palate and soft palate. C: Group III. Defects involving the soft palate to the alveolus, 
usually involving the lip. D: Group IV. Complete bilateral clefts (Tewfik et al., 2011).  
 
 
2.4. Kernahan and Stark classification (Figure 4) 
The Kernahan and Stark classification highlights the anatomic and embryonic 
importance of the incisive foramen. This system provides a graphic 
classification scheme using a Y-configuration, which can be divided into nine 
areas, as follows: 
Areas 1 and 4 – Lip 
Areas 2 and 5 – Alveolus 
Areas 3 and 6 – Palate between the alveolus and the incisive foramen 
Areas 7 and 8 – Hard palate 





Figure 4. Kernahan and Stark classification 
Areas 1 and 4 – Lip; Areas 2 and 5 – Alveolus; Areas 3 and 6 – Palate between the 
alveolus and the incisive foramen; Areas 7 and 8 – Hard palate; Area 9 – Soft palate.  
R = right; L = left (Kernahan, 1971). 
 
 
2.5. International Confederation for Plastic and  
Reconstructive Surgery classification: 
The International Confederation for Plastic and Reconstructive Surgery (1967) 
established a classification of OC based on the embryology of the developing 
structures (Millard, 1976). 
– Clefts of the primary palate 
 Lip 
 Alveolus 
–  Clefts of the primary and secondary palate 
 Lip 
 Alveolus 
 Hard palate (secondary palate) 
–  Clefts of the secondary palate 
 Hard palate 
 Soft palate 
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Classifications of OC based on etiology or pathogenesis provide insufficient 
information regarding the severity of the cleft and the types of direct medical 
and surgical management required. It is necessary to combine the classifications 




Figure 5. Types of clefts  
a. unilateral cleft of the soft palate; b. unilateral cleft lip; c, d unilateral cleft lip and 
palate; e. bilateral cleft of the soft palate; f. bilateral cleft lip; g,h. bilateral cleft lip and 




3.1. CL/P prevalence  
According to the International Perinatal Database of Typical Orofacial Clefts 
(IPDTOC, 2011) the overall prevalence of CL/P is 9.92 per 10,000 worldwide. 
The prevalence of CL is 3.28 per 10,000 and that of cleft lip and palate (CLP) 
6.64 per 10,000. According to the IPDTOC study (2011), in the evaluation of 
geographical areas, the registries in Japan, Mexico, South America, Western 
Europe and Canada have a higher prevalence of CL/P than the overall estimate, 
while the registries in Eastern Europe, South-Mediterranean Europe and South 
Africa reported a lower prevalence. 
Asian and Native American populations have the highest reported birth 
prevalence rates, which are often as high as 1 in 500. European-derived 
populations have intermediate prevalence rates at approximately 1 in 1,000, and 
African-derived populations have the lowest prevalence rates at approximately 




3.2. CP prevalence 
CP is a common congenital anomaly affecting about 1 in 2,000 livebirths 
worldwide. Most CP cases occur as an isolated congenital malformation, but 
they are often part of chromosomal aberrations and monogenic syndromes or 
are associated with other congenital malformations (Shaw et al., 1995; Schutte 
and Murray, 1999; Beaty et al., 2002). 
The prevalence of CP varies significantly in Europe, not only between 
registries but also within countries, with a European mean value of 6.2/10,000 
(EUROCAT, 1995, 1997, 2002). The highest prevalence (14.2/10,000) of 
isolated CP was confirmed in Finland (Finland National Institute for Health and 
Welfare, 2011). 
 
4. Cleft proportion 
The proportion of different types of cleft is providing clues about the 
underlining etiology. In most of the studies from Europe and the U.S. about 
nonsyndromic OC, unilateral CLP is the most frequent, accounting for about 
30–35% of cases. Isolated CL and CP each account for between 20–25% and 
(BCLP) is about 10% (Wyszynski, 2002). 
The left unilateral cleft is a most common finding and seems to be a common 
feature in all ethnic groups (Tolarova, 1987). The left side is affected twice as 
often as the right side (Dixon et al., 2011). 
Fogh-Andersen (1942) reported a CL:CLP:CP ratio of 1:2:1, which is often 
described as the normal ratio for different cleft types in Caucasians. Studies 
from Japan and Africa (Natsume and Kawai, 1986; Ogle, 1993) reveal a much 
lower prevalence of CP. 
 
5. Gender ratio 
The gender ratio among individuals with CL/P is distorted in the general 
population, with males being affected two times more frequently than females. 
The opposite situation, a significantly higher incidence of females compared to 
males, is found for CP (EUROCAT, 200; Dixon et al., 2011). No generally 
accepted explanation for the sex differences is reported. The discovery of the X-
linked CP and ankyloglossia gene TBX22 (Braybrook, 2001; Marçano et al., 
2004) may suggest a candidate gene that might be relevant for palate 
morphogenesis and possibly play a role in the imbalanced sex prevalence of CP 
cases (Marçano et al., 2004). 
 
 
6. Surveillance system 
National statistics regarding OC in Estonia are non-existent. Currently, the only 
way to estimate the number of children affected by clefts is to use the pre-
existing information from previous visits to maxillofacial surgeons. The data 
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retrieved in this way can be significantly distorted, as patients have an 
opportunity to carry out surgical procedures outside Estonia. 
We used the Health Insurance Fund’s diagnosis code database to identify 
primary cases of clefts. Unfortunately, doctors use codes in different ways and a 
first-time patient’s code is reused on recurring patients over many years. 
Due to a lack of official data on clefts in Estonia, national data is also absent 
in different organizations’ overviews. 
 
 
7. Specific exposures 
Population-based studies have shown that non-genetic factors play an important 
role in clefting. 
 
7.1. Cigarette smoking 
The proportion of clefts attributable to maternal smoking in populations with a 
high prevalence of smoking in women of reproductive age was estimated at 
22% (Little et al., 2004a). In many countries, tobacco use is rapidly increasing 
in women of reproductive age because they are actively targeted by tobacco 
marketing campaigns (Windsor, 2002). Several studies have demonstrated 
conflicting results. Maternal smoking has been linked to CL/P in offspring 
(Little et al., 2004b; van Rooij et al., 2001; Wyszynski, 2002a,b). A different 
study has linked smoking during pregnancy to dose-related OC in newborns 
(Wyszynski, 2002a,b). Another study found an association between maternal 
smoking and CP, but not maternal smoking and CL/P (Meyer et al., 2004). In 
addition, it is possible that there may be a strong interaction between certain 
maternal and/or infant gene variants and smoking leading to OC in an infant 
(Shaw et al.,1996; Fallin et al., 2003; Lammer et al., 2004a). A gene-
environment interaction has been found in the occurrence of OC in children 
with the rare allele C2 of the transforming growth factor alpha (TGF-α) gene, 
who were born to women who smoked during pregnancy (Shaw et al.,1996). 
 
 
7.2. Medication and drugs  
Epidemiological studies have linked certain drugs during pregnancy to a higher 
risk of having a child with OC. Maternal intake of vasoactive drugs, such as 
pseudoephedrine, aspirin, ibuprofen, amphetamine, cocaine, or ecstasy, have 
been associated with a higher incidence rate for OC (Beaty et al., 1997; Lam-
mer et al., 2004b). Anticonvulsant medications such as phenobarbital, valproate, 
trimethadione and dilantin have been documented as increasing the incidence of 
CL/P (Harden, 2009; Holmes et al., 2004; Källen, 2003; Wyszynski and Beaty, 
1996). However, there is some question as to whether this increase is due to the 
medications or the underlying epilepsy (Wyszynski and Beaty, 1996). The 
association between antiepileptic drugs and OC may be related to the fact that 
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many antiepileptic drugs reduce plasma folate levels (Schwaninger et al., 1999). 
Isotretinoin has been identified as a potential causative factor for OC (Benke, 
1984; Lammer et al., 1985). Diazepam (Valium) and Bendectin have not been 
found to increase the rate of OC (Mitchell et al., 1981; Rosenberg et al.,1983). 
An association between maternal intake of sulfasalazine, naproxen, and 
glucocorticoids during the first trimester and clefting in newborn has been 
suggested (Källen, 2003). Aminopterin (an anticancer drug) has also been 
linked to the development of OC (Warkany, 1978). 
Corticosteroids are first-line drugs used to treat a variety of conditions in 
women of childbearing age; in animal models the role of corticosteroids in 
clefting is well documented. 
Corticosteroids, either used topically or systemically, have shown a weak 
association with an increased risk of orofacial clefting (Edwards et al., 2003; 
Pradat et al., 2003).  
7.3. Alcohol 
The teratogenicity of alcohol has been demonstrated in animal models (Cudd, 
2005). It has been established that alcohol is a teratogen in humans, most 
clearly in the etiology of fetal alcohol syndrome. Several studies have shown 
that maternal alcohol intake may increase the risk of OC (Lorente et al., 2000a; 
Shaw et al., 1999a). However, this association was not repeated in another study 
(Meyer et al., 2003). Almost all studies have used different definitions for 
alcohol intake but, despite these differences, these studies consistently 
demonstrated, with only a few exceptions, an association between high alcohol 
intake and an increased risk of CL/P (Lorente et al., 2000a; Shaw et al., 1999a). 
Heavy drinking during pregnancy is uncommon, and the small numbers of 
exposed women in many studies have made it difficult to assess this asso-
ciation. A possible mechanism for alcohol-induced embryonic malformations is 
ethanol inhibition of retinoic acid synthesis during embryogenesis (Kot-
Leibovich and Fainsod, 2009). When consumed at high levels, ethanol 
competitively inhibits the production of retinoic acid which is necessary for 
normal cranial neural crest development. 
Studies have found that the infant ADH1C (alcohol dehydrogenase) geno-
type is associated with the risk of CL/P (Jugessur et al., 2009; Boyles el al., 
2010). Alcohol-metabolizing genes are expressed in placental tissue during the 
first trimester of pregnancy (Edenberg et al., 2006), when the critical stages of 
facial development occur.  
 
 
7.4. Diet and vitamins 
It has been suggested that nutrition plays a role in the manifestation of OC. 
Maternal periconceptional use of folic acid has been found to reduce the risk of 
neural tube defects. As a result, the question has been raised about whether 
there is a similar protective effect for other birth defects, including OC. 
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Maternal multivitamin use has been found to result in a significant reduction in 
CP risk and a nonsignificant reduction in CL risk (Werler et al.,1999). Several 
studies have shown decreased rates of CL/P cleft lip and palate with folic acid 
use (Malek et al., 2003; Shaw et al., 1995; Shaw et al., 2002, Tolarova and 
Harris, 1995), while other studies have failed to find such an effect (Hayes et 
al., 1996). Some ambiguity in the studies may be explained by a study that 
found OC risk can be reduced only by consuming high doses of folic acid at the 
time of lip and palate formation (Czeizel et al., 1999). A reduction in the risk of 
OC has been reported with the use of zinc and B vitamins (Munger et al., 2004, 
Krapels et al., 2004), as well as vitamin A (Mitchell et al., 2003). In addition, 
offspring of mothers with the MTHFR 677TT or MTHFR 1298CC genotype and 
low periconceptional folate intake were found to have an increased risk of CL/P 
(Jugessur et al., 2003b; van Rooij et al., 2003). 
 
 
7.5. Solvents and pesticides 
Maternal occupational exposure to glycol ethers, a chemical found in various 
domestic and industrial products, has been found to increase the rate of CL 
(Cordier et al., 1997). Exposure to organic solvents (xylene, toluene, acetone) 
has also been reported to increase the rate of this defect (Wyszynski and 
Beaty,1996). Maternal occupations involving hazardous chemicals such as 
hairdressing, agriculture, and leather or shoe manufacturing, as well as exposure 
to pesticides, lead, and aliphatic acids, have been reported to increase rates of 
OC (Garcia and Fletcher, 1998; Lorente et al., 2000; Wyszynski and Beaty, 
1996); however, other studies failed to find a link between pesticides and OC 
risk (Shaw et al., 1999a; Wyszynski and Beaty, 1996). One study (Irgens et al., 
1998) failed to find any link between parental occupational exposure to lead and 
OC risk. However, the number of cases in the study was small, and the lead 
exposure was measured by census records. Maternal exposure to general 
laboratory chemicals was not seen as significant, although exposure to organic 
solvents, specifically benzene, was found to be a contributing factor in the 
increase of neural crest malformations in offspring, including orofacial clefting 
(Wennborg et al., 2005). 
Living in proximity to hazardous waste facilities does not appear to increase 
the risk for CL/P (Croen and Shaw, 1997), nor does parental occupational 
exposure to 50 Hz magnetic fields (Blaasaas et al., 2002). Studies have been 
unable to find conclusive evidence of an effect from exposure to water 
chlorination and chlorination byproducts (Hwang and Jaakkola, 2003). 
One study (Shaw et al., 1999b) found that periconceptional use of electric 
bed-heating devices (electric blankets, bed warmers, and heated waterbeds) did 
not appear to affect the risk of OC. Maternal fever was associated with 
increased risk, but the intake of multivitamin supplements appeared to lower 
this risk (Botto et al., 2002). 
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8. Parental age 
Several studies have reported an increased risk of OC with increased maternal 
age (Shaw et al., 1991). However, larger studies have failed to identify ad-
vanced maternal age as a risk factor for OC (Abramowicz et al., 2003, Vallino-
Napoli et al., 2004, González et al., 2008). Conversely, another study found a 
greater risk for CL among younger mothers (Reefhuis and Honein, 2004).
  
 
9. Genetic approaches 
To date, genetic approaches to nonsyndromic CLP have included: linkage 
analysis; association studies; identification of chromosomal anomalies or 
microdeletions in cases; and direct sequencing of DNA samples from affected 
individuals (Dixon et al., 2011). 
These methods can be applied to candidate genes or genome-wide strategies 
can be used. Each approach has its own advantages and disadvantages, some of 
which will depend on the underlying genetic architecture of the disease, as well 
as the realities of economics and technology.  
 
 
9.1. Linkage studies 
Findings of linkage studies have suggested various loci could have a causal role 
in CL/P, including regions on chromosomes 1, 2, 4, 6, 14, 17, and 19 (MTHFR, 
TGF-α, D4S175, F13A1, TGF-β3, D17S250, and APOC2), with putative loci 
suggested at 2q32–q35 and 9q21–q33 (Marazita et al., 2004a). Inconsistent 
results could be caused by the small size of the studies or genetic heterogeneity.  
 
 
9.2. Association studies 
Various genetic polymorphisms have been investigated in population-based 
association studies. Some genes function as growth factors (eg, TGF-α, TGF-
β3), transcription factors (MSX1, IRF6, TBX22), or factors that play a part in 
xenobiotic metabolism (CYP1A1, GSTM1, NAT2), nutrient metabolism 
(MTHFR, RARA) or immune response (PVRL1, IRF6) (Mossey et al., 2009). 
The most intensively investigated genes have been the TGF-α (Mitchell, 1997; 
Zeiger et al., 2005; Vieira, 2006) and MTHFR (Chevrier et al., 2007; Vieira et 
al., 2005a) genes. 
Inconsistent data have demonstrated the challenges of researching gene-
disease associations and related interactions. However, IRF6 has shown con-
sistent evidence of association with CL/P across populations of different 
ancestry (Zucchero et al., 2004; Park et al., 2007; Jugessur et al., 2008; 




9.3. Identification of chromosomal anomalies or microdeletions 
Analysis of chromosomal anomalies in patients has proven to be a productive 
route for the identification or confirmation of CL/P loci, with recent successes 
for FGFR2 (Osoegawa et al., 2008) and SUMO1 (Alkuraya et al., 2006; Shi et 
al., 2009; Mostowska et al., 2010). 
 
 
9.4. Targeted resequencing studies 
Targeted resequencing studies of candidate genes have found specific variants 
that might underlie associations with clefting, with the strongest current 
evidence for mutations in MSX1 (Jezewski et al., 2003; Vieira et al., 2005b), 
FGFR1 and FGF8 (Riley et al., 2007a; Riley et al., 2007b), and BMP4 (Suzuki 
et al., 2009). Resequencing studies have also identified private missense 
mutations as rare causes of nonsyndromic orofacial clefts, including TGF-β3 
(Lidral et al.,1998); MSX1 (Jezewski et al., 2003; Vieira et al., 2005b); TBX22 
(Marçano et al., 2004); FOXE1, GLI2, JAG2, LHX8, MSX2, SKI, SPRY2, and 
TBX10 (Vieira et al., 2005b); PTCH1 (Mansilla et al., 2006); PVR and PVRL2 
(Warrington et al., 2006); RYK (Watanabe et al., 2006); FGFs and FGFRs 
(Riley et al., 2007a; Riley et al., 2007b). 
The missense mutations reported in the candidate genes listed above do not 
clearly segregate in families; suggested reasons for this include variable impact 
on gene expression levels during embryonic development and incomplete 
penetrance (Vieira, 2008).  
 
 
9.5. Genome-wide association (GWA) studies  
Findings from recent GWA studies have significantly improved our under-
standing of genes and pathways that contribute to the etiology of nonsyndromic 
CL/P. The first GWA scan reported a new major susceptibility locus at 
chromosome 8q24.21 (Birnbaum et al., 2009), which was independently 
confirmed in several samples (Grant et al., 2009; Nikopensius et al., 2009; 
Beaty et al., 2010). No known genes have been reported within the region of 
association on 8q24.21. According to the University of California, Santa Cruz 
(UCSC) genome browser, the nearest flanking gene is CCDC26, which encodes 
a retinoic acid-dependent modulator of myeloid differentiation. Because 
exposure to retinoic acid is known to induce orofacial clefts, CCDC26 could be 
considered as a potential candidate gene. Four additional susceptibility loci not 
previously associated with CL/P that achieved genome-wide significance have 
been subsequently identified at chromosomes 10q25.3 (VAX1), 17q22 (noggin), 
1p22.1 (MAFB) and 20q12 (ABCA4) (Nikopensius et al., 2010; Mangold et al., 
2010; Beaty et al., 2010). 
The lack of consistency in evidence of association for possible candidate loci 
across studies, where results have mostly been modest, justifies further 
investigation into the relevance of previous findings, in new samples obtained 
from a different ethnic background.  
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10. Genes implicated in lip and palate development 
Fogh-Andersen (1942) provided the first population-based evidence that OC 
has a strong genetic component. Fraser (1970) separated cleft palate only (CPO) 
and CL/P. There is evidence that families with patients affected by OC have a 
different genetic background. Conventionally, it has been decided to classify 
patients with CP only and the remaining patients as CL/P.  
The high rates of familial occurrences, recurrence risks, and elevated concor-
dance rates in monozygotic twins provide evidence for a strong genetic com-
ponent in nonsyndromic CL/P. The disorder has a complex inheritance pattern 
with no clear mode of inheritance and reduced penetrance, with a positive 
family history for clefting in approximately one third of patients. A sibling risk 
ratio of approximately 40 has been reported, and there is a 2–5% increased risk 
for offspring of affected individuals. Concordance in monozygotic twins ranges 
between 40% and 60%, but it is only 5% in dizygotic twins (Mitchell and Risch, 
1992; Carinci et al., 2000; Carinci et al., 2003; Carinci et al., 2007).  
The lack of total concordance in monozygotic twins suggests that genetic 
factors alone do not fully account for the pathogenesis of the phenotype; this 
discordance may be a result of either some degree of nonpenetrance, perhaps as 
a consequence of random developmental events, or environmental influences in 
utero. However, the highly increased monozygotic twin concordance does 
strongly support a major genetic component to orofacial clefting (Stanier and 
Moor, 2004; Mitchell and Risch, 1992).  
The advent of gene targeting technology and basic conventional techniques 
using animal models has led to the identification of genes associated with 
known and unknown etiologic factors. Animal models, with clefts arising 
spontaneously or as a result of mutagenesis experiments, provide another 
exciting avenue for gene mapping. The mouse is an excellent model for 
studying human clefting because the development of craniofacial structures in 
these two species is remarkably similar. Whereas CP is a common phenotype in 
the mouse, CL is rare (Juriloff, 2002). Conservation of genes and linkage 
relationships between mice and humans is well documented, and the 
chromosomal location of a gene in humans can often be predicted from its 
genetic map position in mice. Development of the orofacial complex is very 
similar between mouse and human embryos, and much of the understanding of 
developmental mechanisms in humans has been inferred from mice (Diewert 
and Wang, 1992). It has become evident that CL/P is heterogeneous, and 
different chromosome regions such as 1q, 2p, 4q, 6p, 14q and 19q have been 
claimed to contain a clefting locus (Marazita et al., 2004). 
 
 
10.1. Syndromic forms 
There are over 720 known syndromes featuring OC as cardinal symptoms, with 
etiologies including single-gene defects, teratogens, chromosomal abnormalities 
and those with uncertain etiology. Most orofacial clefts are believed to be 
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nonsyndromic, with the rare syndromic cases resulting from factors such as 
chromosomal abnormalities, characterized Mendelian single-gene syndromes 
and teratogenic effects (Stanier and Moore, 2004). In approximately 35–50% of 
CP and 7–15% of CL/P, other physical abnormalities are seen in the affected 
individual (Gorlin and Cohen, 2001). 
 
 




Apert syndrome CP FGFR2 Gritli-Linde, 2008; Kreiborg 
and Cohen, 1992; Martelli et al., 
2008; Park et al.,1995; Wilkie et 
al.,1995; Moloney et al.,1996. 
Bamforth-Lazarus syndrome CP FOXE1 Gritli-Linde, 2008; Castanet et 










P63 Gritli-Linde, 2008; Celli et  
al., 1999; McGrath et al., 2001.  
Fetal alcohol syndrome CL/P ADH1B Abel, 2006; Green et al., 2007; 
Seki et al., 2005; Wattendorf 
and Muenke, 2005. 
Hereditary lymphoedema-
distichiasis syndrome 
CP FOXC  Fang et al.,2000. 
Kallmann syndrome CP FGFR1  Gritli-Linde, 2008; Dode et al., 
2007; Dode et al., 2003.  
Margarita Island ectodermal 
dysplasia 
CL/P PVRL1  Gritli-Linde, 2008; Suzuki et al., 
2000. 
Pierre-Robin sequence CP SOX9 Dixon et al., 2011. 
Smith-Lemli-Opitz 
syndrome 
CP DHCR Gritli-Linde, 2008; Muenke, 
2002; Wassif et al., 1998. 
Stickler syndrome CP Col11A1, 
Col11A2, 
Col2A1 
Dixon et al., 2011; Wilkin et 
al.,1998. 
Treacher Collins syndrome CP TCOF1  Dixon et al., 2006; Valdez et al., 
2004.  
van der Woude syndrome CP; 
CL/P 
IRF 6  Gritli-Linde, 2008; Kondo et al., 
2002. 
X-linked mental retardation 













Crouzon syndrome CP FGFR2 Dixon et al., 2011; Wilkie et al., 
1995. 
Unnamed syndrome: 
Holoprosencephaly 7, a 
spectrum of forebrain and 
midline anomalies  
CL PTCH Gritli-Linde, 2008; Muenke, 
2002; Ribeiro et al., 2006. 
Unnamed syndrome: CP, 
craniofacial anomalies, 
osteoporosis, and cognitive 
defects 




spectrum of anomalies 
ranging from severe 
(cyclopia) to subtle midline 
asymmetries 
CL/P SHH Gritli-Linde, 2008; Muenke, 
2002. 
Unnamed syndrome: 
Anomalies with most 
features of DiGeorge/ 
velocardiofacial syndromes: 
thymus and parathyroid 
gland hypoplasia, vertebra, 
facial and cardiac outflow 
anomalies.  
CP TBX1 Moreno et al., 2009; Gritli-
Linde, 2008; Yagi et al, 2003; 
Cuneo, 2001. 
Unnamed syndrome: X-
linked CP and ankyloglossia 








10.2. Nonsyndromic genes 
Approximately 75% of CL/P and 50% of CP cases are isolated, nonsyndromic 
OCs (Tolarova and Cervenka, 1998; Stoll et al., 2000). 
Most studies of nonsyndromic clefts to date have focused on CL/P rather 
than isolated CP. This has been biased perhaps by the larger numbers of cases, 
easier ascertainment and less confusion from confounding syndromes. 
Mutation screens of more than 20 CL/P candidate genes find that 2–6% of 
the total number of individuals with nonsyndromic CL/P have mutations in 
genes such as MSX1, FOXE1, GLI2, JAG2, LHX8, SATB2, RYK1 and others 
(Jezewski et al., 2003; Vieira et al., 2005b; Watanabe et al., 2006). The large 
majority of individuals with CL/P (94–98%) do not have mutations in any of a 
wide range of plausible candidate genes. 
The role of genetic factors in determining CP is documented by recurrence 
risk (Fraser, 1970) and monozygotic twin concordance (Nordstrom et al., 1996), 
but thus far there is no evidence of any single gene acting as a major factor in 
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the etiology of malformation. In isolated CP, a major genetic component with a 
relatively small number of interacting causative loci has been suggested and the 
final phenotype is the result of gene products that interact in many ways with 
one another and the environment. 
 
 
Table 3. Candidate genes for oral clefts (Dixon et al., 2011) 
 
Gene Location Evidence References 
Confirmed 
IRF6 1q32 GWA, LD, L, M Zucchero et al., 2004; Blanton et al., 
2005; Ghassibe et al., 2005; Scapoli 
et al., 2005; Srichomthong et al., 
2005; Rahimov et al., 2008; 
Marazita et al., 2009; Birnbaum et al., 
2009. 
 8q24 locus GWA, LD Birnbaum et al., 2009; Grant et al., 
2009; Beaty et al., 2010. 





 GWA Beaty et al., 2010. 
MSX1 4p16 
 
LD, M Van der Boogaard et al., 2000; 
Maestri et al., 1997; Mitchell et al., 
2001; Romitti et al., 1999; Jezewski, 
2003; Lidral et al., 1998; Vieira et al., 
2003; Suzuki et al., 2004. 
FOXE1 9q22 L, LD, M Vieira et al., 2005b; Venza et al., 
2006; Moreno et al., 2009a. 
FGFR2 10q26 M Riley et al., 2007; Riley and Murray, 
2007; Osoegawa, 2008. 
BMP4 14q22–q23 M Lin et al., 2008; Suzuki et al., 2009; 
Jianyan et al., 2010. 
 17q22 locus GWA Beaty et al., 2010; Mangold et al., 
2010. 
MAFB 20q12 GWA Beaty et al., 2010.  
MYH9 20q13 LD Birnbaum et al., 2009; Martinelli et 
al., 2007; Chiquet et al., 2009;  




Gene Location Evidence References 
Intensively studied 
MTHFR 1p36.3 LD Martinelli et al., 2001; Blanton et al., 
2000; Botto and Yang, 2000; 
Jugessur et al., 2003b; Jagomägi et 
al., 2010. 
TGF-α 2p13 LD Marazita and Mooney, 2004; 
Mitchell, 1997; Hwang et al.,1995; 
Maestri et al.,1997; Miettinen et al., 
1989; Suzuki et al., 2004; Carter et 
al., 2010. 
SUMO1 2q33 M Alkuraya et al., 2006; Shi et al., 
2009; Mostowska et al., 2010; Carter 
et al., 2010. 
PDGFC 4q32 LD, M Ding et al., 2004; Choi et al., 2009; 
Jugessur et al., 2009. 
FGF8 10q24 M Riley and Murray, 2007; Riley et al., 
2007. 
PVRL1 11q23 M, LD Avila et al., 2006; Sözen et al., 2001; 




14q24 LD, M Miettinen et al.,1999; Maestri et 
al.,1997; Hwang, 1992; Lidral et 
al.,1998; Suzuki et al., 2004; Beaty et 
al., 2002; Suazo et al., 2010. 
CRISPLD2 16q24 LD Chiquet et al., 2007; Letra et al., 2010 
GSTT1 22q11 LD Shi et al., 2007 
 
GWA = genome-wide association; LD = linkage disequilibrium; L = linkage;  
M = mutation detection 
 
 
10.2.1. Chromosome 1  
10.2.1.1. IRF6 – interferon regulatory factor 6; 1q32.3–q41 
IRF6 belongs to a family of nine transcription factors which regulate the 
expression of interferon-alpha and interferon-beta after viral infection. Zucchero 
et al. (2004) found evidence for overtransmission of several single nucleotide 
polymorphisms (SNPs) in IRF6 in nonsyndromic CLP, several of which were 
confirmed by others (Blanton et al., 2005; Scapoli et al., 2005; Diercks et al., 
2009; Jia et al., 2009). 
Mutations in the IRF6 gene are known to be associated with van der Woude 
syndrome and popliteal pterygium syndrome. Variation at the IRF6 locus is 
responsible for 12% of the genetic contribution to CL/P at the population level 
and triples the recurrence risk for a child with a cleft in some families 
(Houdayer et al., 2001; Zucchero et al., 2004; Scapoli et al., 2005).  
Although the role of IRF6 during embryonic development has been 
identified, its function and regulation still remain poorly understood. IRF6 
belongs to the IRF family of transcription factors. This gene encodes interferon 
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regulatory factor 6, which is a key element in oral and maxillofacial develop-
ment. IRF6 is highly expressed in the leading edge ectoderm of the palatal 
shelves before and during formation of the primary palate (Knight et al., 2006; 
Washbourne and Cox, 2006). It has been shown that IRF6-null mice have 
abnormal skin, limb, and craniofacial development (Kondo et al., 2002). 
A positive association between IRF6 variants and OC has been confirmed in 
multiple populations and independently replicated (Vieira et al., 2007a). Meta-
analysis of 13 genome scans confirmed that IRF6 is one of the main candidate 
genes that has common polymorphic variants, which can increase the risk of 
CL/P (Marazita et al., 2004). 
Further functional analyses to identify downstream target genes and 
interacting proteins is important to the understanding of the role of IRF6 in 
palatal development, especially given (1) the overlap of IRF6 gene expression 
at the medial edge of the palatal shelves immediately before and during fusion 
with that of transforming growth factor beta 3 (TGF-β3) in mice, and (2) the 
proposed role of the SMIR domain of IRF6 in mediating interactions between 
IRFs and Smads, a family of transcription factors known to transduce TGF-β 
signals (Fitzpatrick et al., 1990; Brivanlou & Darnell, 2002). 
It has been shown that integration of IRF6 and the Notch ligand Jagged2 
function is essential for the control of palatal adhesion and fusion competence 
via a combined role in the control of oral periderm formation and differentiation 
(Richardson et al., 2009). 
 
Van der Woude syndrome (VWS). 
VWS represents the most common single-gene cause of cleft lip and cleft 
palate, accounting for about 2% of all individuals with CL/P (Cohen and 
Bankier, 1991; Murray et al., 1997) or roughly one in 35,000 to one in 100,000 
in the European and Asian populations (Cervenka et al., 1967; Rintala and 
Ranta, 1981; Burdick, 1986).  
Patients with VWS have clefts of the lip and palate, missing teeth in 
approximately 25% of cases, and pits in the lower lip in approximately 85% of 
cases. Both cleft types, CL/P and CP only, occur in individuals with VWS in 
the same proportions as in the general population, about two to one respectively 
(Burdick et al., 1987). Oberoi and Vargervik (2005) suggest that individuals 
with VWS are more likely to have hypoplasia of the mandible and maxilla than 
isolated cases with the same cleft phenotype.  
Sequence analysis of the IRF6 coding region (exons 1 through 9) detects 
mutations in approximately 70% of individuals with VWS. Mutations in exons 
3, 4, and 7–9 account for 80% of known VWS-causing mutations (Shutte and 
Murray, 1999). 
 
Popliteal pterygium syndrome (PPS). 
Prevalence is approximately one in 300,000. The PPS phenotype includes CL/P 
in approximately 91–97% of individuals; fistulae of the lower lip in 45% of 
cases (Froster-Iskenius, 1990); webbing of the skin extending from the ischial 
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tuberosities to the heels, bifid scrotum and cryptorchidism in males, hypoplasia 
of the labia majora in females, syndactyly of fingers and/or toes, and anomalies 
of the skin around the nails (Rintala and Lahti, 1970).  
Most missense mutations that cause PPS are located in IRF6 exon 4. It 
appears likely that certain mutations (R84H, R84C) are more apt to cause PPS 
than VWS. A cluster of missense mutations in the DNA-binding domain are 
more commonly seen in families with PPS. However, families may include 
individuals with features of only VWS, and other members with the additional 
features of PPS.  
10.2.1.2. MTHFR – methylenetetrahydrofolate reductase; 1p36.3 
MTHFR is an important enzyme in folate metabolism. The MTHFR gene en-
codes an enzyme called methylenetetrahydrofolate reductase. This enzyme 
plays a role in processing amino acids, the building blocks of proteins. 
Methylenetetrahydrofolate reductase is important for a chemical reaction 
involving forms of the vitamin folate (also called folic acid or vitamin B9). 
Specifically, this enzyme converts 5,10-methylenetetrahydrofolate to 5-
methyltetrahydrofolate. This reaction is required for the multistep process that 
converts the amino acid homocysteine to another amino acid, methionine. The 
body uses methionine to make proteins and other important compounds. 
In 1998, Shaw reported an association between CL/P and genetic variation at 
the MTHFR locus. Since that initial report, there have been a number of studies 
reporting the association between CL/P and MTHFR variant (Mills et al., 1999; 
Martinelli et al., 2001). The gene encoding the MTHFR enzyme is known to 
have at least two functional polymorphisms: 677 C>T (rs1801133, c.665C>T, p. 
Ala222Val) and 1298 A>C (rs1801131, c.1286A>C, p. Glu429Ala). The 
homozygous MTHFR 677TT genotype results in a thermolabile enzyme with 
reduced activity (Molloy et al., 1997). A second polymorphism in the MTHFR 
gene, an A-to-C substitution at nucleotide 1298, also results in decreased 
MTHFR activity but is not associated with higher homocysteine or lower 
plasma folate levels (Van der Put, 1998). Animal studies suggest that a 
decreased conversion of homocysteine to methionine could be a crucial step in 
causing neural tube defects. It has been shown that rat embryos in culture 
require methionine for neural tube closure (Mills et al., 1996). Several case-
control studies have attempted to implicate this polymorphism in clefting 
etiology but results have not been encouraging. Associations have only been 






10.2.2. Chromosome 2 
10.2.2.1. TGF-α – Transforming growth factor alpha; 2p13 
Transforming growth factors (TGFs) are biologically active polypeptides that 
reversibly confer the transformed phenotype on cultured cells.  
The TGF-α receptor is identical to the epidermal growth factor (EGF) 
receptor. TGF-α shows about 40% sequence homology with EGF and competes 
with EGF for binding to the EGF receptor, stimulating its phosphorylation and 
producing a mitogenic response.  
The biological activities of TGF-α resemble those of EGF since both factors 
bind to the same receptor. Some biological activities of TGF-α are, however, 
stronger than those of EGF. TGF-α is thought to be the fetal form of EGF. The 
physiological role of TGF-α is probably the control of epidermal development 
during development and differentiation of the cells (Ardinger et al., 1989). 
TGF-α also affects bone formation and remodelling by inhibition of the 
synthesis of collagen and release of calcium. These effects are more pronounced 
than those of EGF. TGF-α also promotes the generation of osteoblast-like cells 
in long-term bone marrow cultures.  
The first study showing association of TGF-α with CL/P was by Ardinger in 
1989, and many additional studies have replicated this finding (Marazita and 
Mooney, 2004; Mitchell, 1997; Hwang et al., 1995; Maestri et al.,1997; 
Miettinen et al., 1989; Suzuki et al., 2004; Carter et al., 2010). However, other 
studies have not been able to replicate this finding by either linkage or 
association (Jugessur et al., 2003a; Passos-Bueno, 2004). A study combining 13 
linkage scan studies (Marazita et al., 2004), revealed positive results, cor-
roborating the hypothesis that TGF-α is a modifier rather than being necessary 
or sufficient to cause clefting. 
Chromosomal abnormalities involving only duplication of chromosome 2q 
are rare. Duplication within the long arm of chromosome 2 may cause CPO and 
Pierre Robin sequence (Õunap et a., 2005). 
 
 
10.2.3. Chromosome 4 
10.2.3.1. MSX1 – msh homeobox; 4p16.3–p16.1  
MSX genes are homeobox-containing genes homologous to the Drosophila msh 
gene (Hill et al., 1989). MSX proteins function as transcriptional repressors in 
cellular differentiation (Catron et al., 1996) and interact with other protein 
factors to modulate differentiation and proliferation (Zhang et al., 1997). 
Embryonic expression patterns of MSX genes are consistent with the role of 
Msx proteins in epithelial-mesenchymal tissue interactions during craniofacial 
development (Hill et al., 1989). The role of Msx proteins in active morpho-
genesis is suggested by the lack of Msx1 expression in cells undergoing 
terminal differentiation (Woloshin et al., 1995) and by restricted cellular 
expression of Msx1 transcript during periods of rapid cellular proliferation 
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(Simon et al., 1995). Point mutations in MSX1 appear to contribute to 
approximately 2% of all CL/P cases (Jezewski et al., 2003). Msx1-deficient 
mice develop craniofacial abnormalities of the nasal, frontal, and parietal bones, 
as well as CP. The occurrence of CP in Msx1 knockout mice aided the 
identification of a MSX1 mutation cosegregating with tooth agenesis, CL/P and 
CP (van den Boogaard et al., 2000). It has been proposed that CP in Msx1 
knockout mice is due to insufficient palatal mesenchyme (Ferguson, 1994). 
Also, rare human mutations have been observed in MSX1 that are associated 
with tooth agenesis (Vastardis et al., 1996), with and without CL/P (van den 
Boogaard et al., 2000). Association and linkage studies further support a role 
for MSX1 in different populations. 
 
  
10.2.4. Chromosome 6  
10.2.4.1. EDN1 – endothelin-1; 6p24.1 
The protein encoded by this gene is proteolytically processed to release a 
secreted peptide termed endothelin-1. This peptide is a potent vasoconstrictor 
and is produced by vascular endothelial cells. EDN1 also can affect the central 
nervous system. 
Endothelin receptors are widely expressed in all tissues, which is consistent 
with their physiological role as vasoactive peptides. They are also localized to 
non-vascular structures including epithelial cells, glia and neurons. The 
principle physiological role of endothelin receptors is the maintenance of 
vascular tone. 
Knockout mice of EDN1, which is homologous to EDN1 mapping to the 
chromosomal region 6p23 in humans, shows craniofacial abnormalities 
including cleft palate (Kurihara et al., 1994). Pezzetti et al. (2000) examined the 
endothelin gene and three other genes in the endothelin pathway (ECE1, 
EDNRA, EDNRB) as possible candidates for orofacial cleft. Linkage results 
indicated that none of these genes is involved in the pathogenesis of OC. Most 
of the studies have excluded the possibility that the EDN1 pathway plays a 
major role in the etiology of nonsyndromic CL/P in humans (Scapoli et al., 
2002), but several studies have shown some evidence of CL/P locus on the 
6p23–25 regions. Linkage has been found with EDN1 and AP2 genes, and 
balanced translocations and deletions in this region associated with a cleft 
phenotype have been reported (Moreno et al., 2004). 
 
 
10.2.5. Chromosome 9 
10.2.5.1. FOXE1 – forkhead box E1 (thyroid transcription factor 2); 9q22 
Mutations in FOXE1 are associated with congenital hypothyroidism, thyroid 
agenesis and CP in humans (Bamford-Lazarus syndrome, MIM 241850) and 
mice (De Felice et al., 1998; Dathan et al., 2002). The forkhead gene family 
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(FOX), originally identified in Drosophila, encodes transcription factors with a 
conserved 100-amino acid DNA-binding motif called the ‘forkhead domain’ 
and regulates diverse developmental processes in eukaryotes. Rare missense 
mutations in FOXE1 have been associated with isolated clefting (Vieira et al., 
2005b; Venza et al., 2006). 
The study by Marazita et al. (2009) showed the strongest associations with 
families in which one or more affected family members had CL/P, and little or 
no evidence of association in families with CL alone or CP alone. In a cohort of 
CL/P families from Colombia, the United States, and the Philippines, Moreno et 
al. (2009a) tested 397 SNPs spanning 9q22-q33 for association. Significant SNP 
and haplotype association signals narrowed the interval to a 200-kb region 
containing FOXE1, C9orf156, and HEMGN. Association results were replicated 
in CL/P families of European descent; when all populations were combined, the 
two most associated SNPs, rs3758249 (P = 5.01E–13) and rs4460498 (P = 
6.51E–12), were located inside a 70-kb linkage disequilibrium block containing 
FOXE1. Isolated cleft palate was also associated, indicating that FOXE1 may 
play a role in two phenotypes thought to be genetically distinct. 
The involvement of FOXE1 during primary palatogenesis is supported by 
the previously uncharacterized epithelial expression in the medial nasal and 
maxillary processes that will undergo fusion (Marazita et al., 2009). 
 
 
10.2.6. Chromosome 14 
10.2.6.1. TGF-β3 – transforming growth factor, beta 3; 14q24 
Transforming growth factor betas (TGF-β) mediate many cell-cell interactions 
that occur during embryonic development. TGF-β exists in at least five 
isoforms, known as TGF-β1, TGF-β2, TGF-β3, TGF-β4, TGF-β5, that are not 
related to TGF-alpha. Their amino acid sequences display homologies on the 
order of 70–80%. A Tgf-β3 knockout mouse with defective palatogenesis was 
present by Kaartinen (1995). Proetzel et al. (1995) produced Tgf-β-null mice in 
which exon 6 of the TGF-β3 gene was replaced by the neomycin-resistance 
gene. Whereas heterozygotes had no apparent phenotypic change, homozygotes 
had an incompletely penetrant failure of the palatal shelves to fuse, leading to 
CP. The defect appeared to result from impaired adhesion of the apposing 
medial edge epithelial of the palatal shelves and subsequent elimination of the 
midline epithelial seam. Subsequent human studies have yielded both positive 
and negative results (Marazita and Mooney, 2004). 
 
10.2.6.2. JAG2 – Protein jagged-2 precursor; 14q32 
The Notch family of receptors are important signalling molecules regulating 
cell fate during development. Jagged 1 and Jagged 2 proteins play a role in 
craniofacial and limb development. Targeted deletion of the JAG2 exons 
encoding the DSL domain results in craniofacial defects and perinatal lethality 
in mice (Jiang et al., 1998). Jag2 is expressed throughout the oral epithelium 
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and is required for Notch1 activation during oral periderm differentiation. The 
mutant homozygotes exhibited CP and fusion of the tongue with the palatal 
shelves. Jag2 mutant mice have CP mainly due to failure of the palatal shelves 
to elevate and fuse. 
Richardson et al. (2009) showed that Irf6 /Jag2 doubly heterozygous mice 
displayed fully penetrant intraoral epithelial adhesions, resulting in CP. There 
was no evidence of direct interaction between Irf6 and Jag2, suggesting that the 
mechanism underlying the genetic interaction between Irf6 and Jag2 is the 




10.2.7. Chromosome 17 
10.2.7.1. RARA – retinoic acid receptor, alpha; 17q21 
The RARA gene was first reported by Bale et al. (1988). Mattei et al. (1991) 
mapped the RARA genes in humans, mice, and rats, thereby extending the 
homologies among human chromosome 17, mouse chromosome 11, and rat 
chromosome 10. Juriloff and Mah (1995) studied A/WySn-strain mice with a 
high birth prevalence of CL/P, an animal model with a similarly complex 
genetic basis. They mapped a major CL/P-causing gene, clf1, to chromosome 
11 to a region having linkage homology with humans. 
Retinoic acid has a well-established role during development, and members 
of the retinoic acid receptor family mediate its activity. Transgenic and 
knockout mice studies have shown that these genes are important for facial 
development (Lohnes et al., 1994). Various human studies have reported both 
positive and negative results near the RARA gene. Chenevix-Trench et al. 
(1992) first reported a significant difference in the frequency of alleles at the 
RARA locus between nonsyndromic CL/P patients and unrelated controls. 
Vintiner et al. (1993) investigated a group of British CL/P samples and found 
no association or linkage between RARA and the traits. Shaw et al. (1993) 
performed linkage analyses on 14 Indian families in West Bengal, India. They 
also reported no linkage between nonsyndromic OC and RARA. 
 
 
10.2.8. Chromosome 19 
10.2.8.1. PVRL2 – Poliovirus receptor-related 2 (herpes virus entry mediator B); 
19q13.2 
PVRL2 is a transmembrane glycoprotein that belongs to the poliovirus receptor 
family. Mutations in a related protein, PVRL1, are known to cause the 
autosomal recessive Margarita Island clefting syndrome (Suzuki et al., 2000). 
This gene encodes a single-pass type I membrane glycoprotein with two Ig-
like C2-type domains and an Ig-like V-type domain. This protein is one of the 
plasma membrane components of adherent junctions. It also serves as an entry 
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for certain mutant strains of herpes simplex virus and pseudorabies virus, and it 
is involved in cell-to-cell spreading of these viruses. Variations in this gene 
have been associated with differences in the severity of multiple sclerosis. 
Alternate transcriptional splice variants, encoding different isoforms, have been 
characterized (Suzuki et al., 2000). 
 
10.2.8.2. BCL3 – B-cell CLL/lymphoma 3; 19q13.1–q13.2 
BCL3 is a protooncogen that is involved in cell proliferation, differentiation and 
apoptosis. Previous evidence has implicated the role of the BCL3 gene in the 
etiology of nonsyndromic clefting. Several studies have observed an association 
between BCL3 alleles and OC, and the association has been suggested to be due 
to either an allele of low penetrance or BCL3 acting as a modifier locus (Maestri 
et al., 1997; Gaspar et al., 2002). 
 
 
10.2.9. Chromosome X 
10.2.9.1. TBX22 – T-box 22 T-box transcription factor; Xq21.1  
This gene is a member of a phylogenetically conserved family of genes that 
share a common DNA-binding domain, the T-box. T-box genes encode 
transcription factors involved in the regulation of developmental processes. 
Braybrook et al. (2001) identified six different mutations, including missense, 
splice site, and nonsense, in the TBX22 gene in families segregating X-linked 
disorder cleft palate with ankyloglossia (CPX), and it is believed to play a major 
role in human palatogenesis. 
Marcano et al. (2004) analysed the TBX22 gene in a large sample of patients 
with CP with no preselection for inheritance or ankyloglossia. They found 
TBX22 coding mutations in 5 of 200 patients in North American and Brazilian 
cohorts, with an additional four putative splice site mutations. They also 
identified mutations in previously unreported CPX families and presented a 
combined genotype/phenotype analysis of previously reported familial cases. 
Males frequently exhibited CP and ankyloglossia together (78%), as did a 
smaller percentage of carrier females. Mutations within families could result in 
either CP only, ankyloglossia only, or both, indicating that these defects are 
distinct parts of the phenotypic spectrum. 
Andreou et al. (2007) suggested that small ubiquitin-related modifier 
(SUMO) modification may represent a common pathway that regulates normal 
craniofacial development and is involved in the pathogenesis of orofacial 
clefting. He found that TBX22 is a target for SUMO1 and that this modification 
is required for TBX22 repressor activity. SUMO1 haploinsufficiency leads to 
OC (Alkuraya, 2006). Although the site of SUMO attachment at lysine-63 is 
upstream of the T-box domain, loss of SUMO1 modification is consistently 
found in all pathogenic X-linked CP missense mutations. This implies a general 




AIMS OF THE STUDY 
1.  To evaluate the occurrence rate of OC, on the basis of records of patients 
treated in the Department of Oral and Maxillofacial Surgery of the Tartu 
University Hospital, during the period of 1910–2000. 
2.  To determine the rate of occurrence between different cleft types on the 
basis of gender and location.  
3.  To record the epidemiological factors which may influence the development 
of OC, and to evaluate their occurrence regularities. 
4. To investigate the possible contribution of recognized candidate genes in the 
development of nonsyndromic OC in an Estonian population and in the 






MATERIALS AND METHODS 
1. Study population 
For the purpose of the study I (Ref. I), data was collected from the preserved 
database in the Department of Oral and Maxillofacial Surgery at the Stoma-
tology Clinic of Tartu University Hospital. The preserved patient records were 
available for the years 1910 to 2000. During this period of time, a total of 585 
health files of patients with OC had been preserved. In 583 cases, the patient’s 
gender was known (this information was missing in two files). 
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1.  Patients were recruited from surgical clinics in Estonia (North Estonia Medical 
Centre, Tallinn, and Tartu University Hospital). 
2.  Patients were collected at the Riga Cleft Lip and Palate Centre, Institute of Stoma-
tology, Riga Stradins University. 
3.  Patients were collected at the Center for Medical Genetics, Vilnius University Hos-
pital Santariškių Klinikos in collaboration with the largest orthodontic clinics in 
Lithuania. 
4.  Unaffected unrelated individuals without a family history of clefting, collected as 
randomly selected population-based controls from a Biobank of the Estonian 
Genome Center, University of Tartu. 
5.  Controls selected from the Latvian Biomedical Research and Study Center within 
the framework of the national project “Genome Database of Latvian Population”. 
6.  Control sample of Lithuania consists of unrelated individuals who were recruited 
from six different ethnolinguistic groups (i.e., East Aukštaičiai, West Aukštaičiai, 
South Aukštaičiai, West Žemaičiai, South Žemaičiai and North Žemaičiai) with an 
equal male-to-female ratio. 
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All probands from the Lithuanian and Latvian sample from candidate gene 
studies (Ref. III and IV) were identified by an experienced clinical geneticist for 
congenital anomalies or major developmental delays. In the Estonian sample 
(Ref. I, II, III and IV) diagnostic information from clinical geneticists was 
available in patient medical records. Patients with confirmed monogenic 
syndrome or chromosomal aberrations, associated malformations and mental 
retardation were excluded from the study.  
Ethical approval for the study was obtained from the Ethics Review Com-
mittee on Human Research of the University of Tartu, the central Medical 
Ethics Committee of Latvia, and the Lithuanian Bioethics Committee. All indi-
viduals signed an informed consent form for participation in the study. In the 
case of patients who were under18 years of age, consent was obtained from 




2.1. Genes and SNP selection  
We selected candidate genes on the basis of previously published findings from 
association and linkage studies of Caucasian origin on nonsyndromic OC, gene 
expression patterns during craniofacial development, gene-knockout data from 
animal studies, genes that underlie Mendelian syndromic forms of clefting, and 
studies of chromosomal rearrangements associated with cleft phenotypes in 
humans. Selected SNPs were selected to capture all the SNPs with minor allele 
frequencies >0.05 and r2>0.8 in the regions of interest based on the HapMap 
Phase II data, using HapMap CEU as a reference population. Multiple SNPs 
were selected for each gene, including 10–20 kb of both upstream and down-
stream genomic sequences. A list of selected genes in different studies and the 
number of genotyped SNPs per gene are shown in Table 5. 
 
 
Table 5. Candidate genes and loci included in the study  









MTHFR 1p36.3 11 9 8 
LHX8 1p31.1 9 9 9 
COL11A1 1p21  – 42 42 
SKI 1q22-q24 20 19 19 
IRF6 1q32.3-q41 11 10 10 
TGF-α 2p13  – 36 35 
FN1 2q34  – 27 27 
MSX1 4p16.3-p16.1 15 15 15 
FGF2 4q26-q27  – 18 18 
FGF1 5q31  – 31 31 
MSX2 5q34-q35 6 6 6 
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EDN1 6p24.1 15 15 15 
COL11A2 6p21.3  – 19 19 
FGFR1 8p11.2-p11.1  – 11 11 
FOXE1 9q22 4 4 4 
TBX10 11q13.2 10 10 10 
MMP3 11q22.3  – 5 5 
MMP13 11q22.3  – 19 19 
PVRL1 11q23.3 18 17 17 
COL2A1 12q13.11  – 32 32 
SPRY2 13q31.1 3  –  – 
BMP4 14q22-q23  – 4 4 
TGF-β3 14q24 8 8 8 
JAG2 14q32 11 11 11 
MMP25 16p13.3  – 6 6 
MMP2 16q13-q21  – 20 20 
CDH1 16q22.1  – 13 13 
RARA 17q21 5 4 4 
WNT3 17q21  – 16 16 
WNT9B 17q21  – 11 11 
TIMP2 17q25  – 25 25 
‘OFC11’ 18q21a  – 25 25 
BCL3 19q13.1-q13.2 4 3 2 
PVRL2 19q13.2 13 12 12 
CLPTM1 19q13.2-q13.3b 8 7 7 
BMP2 20p12  – 25 25 
MMP9 20q11.2-q13.1  – 6 5 
TIMP3 22q12.3  – 36 36 
TBX22 Xq21.1 5 5 5 
 
a includes SMAD2 and SMAD4 genes 




2.2. Genotyping  
A sample of peripheral venous blood was taken from all participants, for DNA 
extraction. Genomic DNA was extracted from EDTA-preserved blood accor-
ding to standard high-salt extraction (Estonian sample) or phenol-chloroform 
methods (Latvian and Lithuanian samples). SNP genotyping was performed 
using an arrayed primer extension-based genotyping method (APEX-2). This 
method allows multiplex DNA amplification and detection of SNPs, and muta-
tions on microarrays via four-colour single-base primer extension (Krjutškov et 




3. Statistical analysis 
Descriptive statistics were performed using the Statistical Package for the So-
cial Sciences (SPSS) version 14.0 software package. All markers were assessed 
for Hardy–Weinberg equilibrium in controls and affected individuals using a 
Pearson’s chi-square test with one degree of freedom. The alleles at each 
marker were tested for association, twice: first, only individuals with CL/P were 
compared with controls; and, second, only individuals with CP were compared 
with controls. Allelic odds ratios (ORs) and 95% confidence intervals (CIs) 
were estimated using the standard chi-square test, assuming a multiplicative 
model. The level of statistical significance was set at  = 0.05 for nominal 
association without correction for multiple comparisons because of the 
exploratory character of this study. Haplotype-phenotype association tests were 
performed using the standard chi-square test. Statistical analyses were con-





1. Overview of Estonian OC patients 
1.1. Study group outline 
During the period 1910–2000, a total of 585 health files of patients with OCs 
had been preserved. In 583 cases, the patient’s gender was known (this 
information was missing in two files); there were 333 boys (57.1%) and 250 
girls (42.9%) (Figure 6). 
Figure 6. Gender of the patients
 
 












Forty two percent of clefts were CLP, 19% were CL and 39% were CP (Figure 
7). One of the findings of the study, was that there was a high occurrence rate of 
CP: CL (19%), CLP (42%), CP (39%) – a ratio of 1:2:2. 
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The most common cleft type was incomplete cleft palate (30% of patients with 
clefts), the least frequent was bilateral cleft lip (3.8%). The most common cleft 
type for boys was left-side CLP (13.8%) and the most common for girls was CP 
(17.8%). The least frequently occurring cleft was bilateral CL: boys (2.6%) and 
girls (1.2%) (Figure 8). The left side of the face was affected 2.2 times more 





Figure 8. The most common cleft types according to gender and facial involvement.  
 
 
1.2. Epidemiological factors 
Four hundred and eighty-eight patients with clefts also had their birthweight 
marked on their patient records. Of these, 2.6% were born prematurely. The 
average birthweight of children with clefts was 3416 grams (boys 3447 g, girls 
3376 g), and 6.8% had a birthweight of less than 2500 g. Half of the children 
had developmental anomalies.  
In terms of age, 28.4% of mothers and 37.7% of fathers were older than 30 
years; both parents were older than 30 years in 21.9% of cases; 2.6% of mothers 

























































Epidemiological factors which affected the mother in the first trimester of 
pregnancy (Figure 9) included: 
*  Physical factors – 5.8% had physical traumas, 12.9% did heavy physical 
labour and 45% underwent medical abortions before the pregnancy. 
*  Chemical factors – 6.7% had toxicosis during the first trimester, 5.2% had 
hormonal dysbalance, 5.2% had exposure to chemicals. 
*  Biological factors – 9.8% had a common cold, 4% had gynaecological 
disorders. 








2. Genes contributing to the risk  
of nonsyndromic CL/P in Estonia 
We genotyped 176 tag SNPs in 18 candidate genes in 100 CL/P patients and 
205 unrelated controls from the Estonian population. The overall call rate was 
99.62%. There was no significant deviation from the Hardy-Weinberg 
equilibrium for any of the genotyped SNPs. 
Table 6 presents all markers with allelic association test P-values of <0.05 in 
the CL/P case-control sample. Twenty-six polymorphisms in 10 genes, and 9 
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The most significant association with CL/P was found for SNP rs6446693, 
which is located ~6 kb upstream of the muscle segment homeobox 1 (MSX1) 
gene, and this association remained statistically significant after correcting for 
multiple testing. The T allele was associated with significantly higher risk  
(OR = 1.934; 95% CI = 1.366–2.738; P = 1.82  10–4). The SNP rs1907998, 
located ~5 kb upstream of MSX1, was significantly associated with CL/P under 
the assumption of the dominant model of inheritance (P = 8.53  10–5). 
Other markers with interesting P-values in the CL/P dataset included the 
MTHFR, SKI, MSX1, and PVRL2 loci (Table 6). Among markers in or near the 
MTHFR and SKI genes, a variant allele had a protective effect, whereas the 
variant alleles of the MSX1 and PVRL2 markers were associated with an in-
creased risk. 
There was no evidence of a sex-specific component in the association be-
tween CL/P and the nine markers with the best P-values. The genotype dis-
tributions in male and female cases were similar for these SNPs (Armitage’s 
trend test P > 0.05).  
 
Haplotype analysis 
Haplotype analysis was performed only with the CL/P dataset (cases plus 
controls, N = 305). Case-control analysis was performed as single haplotype 
comparisons for haplotypes constructed from SNPs within linkage disequilib-
rium (LD) blocks identified in the MSX1, MTHFR, IRF6, BCL3, TGF-β3, 
PVRL2, EDN1, JAG2, and TBX10 genes. 
 
 
Table 7. Haplotype-phenotype association analysis of the MTHFR gene 
 




























 Cases Controls P 
H1 C T A T G 0.639 0.531 0.0114 
H1 * T A T G 0.660 0.541 0.0053 
H1 * * A T G 0.660 0.544 0.0063 
H2 T G G C * 0.215 0.324 0.0053 
H1 C T A * * 0.659 0.536 0.0038 
H2 T G G * * 0.214 0.326 0.0044 
H1 * T A T * 0.660 0.541 0.0053 
H2 * G G C * 0.235 0.342 0.0069 
H1 * * * T G 0.680 0.567 0.0072 
H1 C T * * * 0.730 0.629 0.0133 
H2 T G * * * 0.215 0.331 0.0030 
H1 * * A T * 0.660 0.544 0.0063 
H2 * * G C * 0.300 0.424 0.0030 
H1 * T A * * 0.680 0.546 0.0016 
H2 * G G * * 0.250 0.352 0.0106 
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 Cases Controls P 
H1 C * A * * 0.658 0.537 0.0045 
H2 T * G * * 0.213 0.327 0.0036 
H1 C * * T * 0.659 0.554 0.0136 
H2 T * * C * 0.214 0.330 0.0029 
H1 * T * T * 0.664 0.553 0.0089 
H2 * G * C * 0.234 0.346 0.0048 
 
 
Table 7 presents the results from haplotype-based association analysis within an 
LD block at the MTHFR locus for all possible 2- to 5-SNP haplotypes with a 
frequency of > 5% among CL/P patients and with a P-value of < 0.01. The best 
results, with P < 0.01, for common (frequency > 5%) 2- to 4-SNP haplotypes in 
other candidate loci are presented in Table 8.  
 
 
Table 8. Most significant results from haplotype-phenotype association analysis of 
studied genes 
 
     Frequency  
Haplotype SNP SNP SNP SNP Cases Controls P 
BCL3        
 rs17728272 rs4803750 rs8100239 rs8103315    
H3 C A T A 0.188 0.109 0.0071 
H3 C * T A 0.188 0.109 0.0071 
MSX1        
   rs6446693 rs1907998    
H1   C A 0.444 0.590 7X10–4 
H2   T G 0.431 0.308 0.0026 
EDN1        
   rs4714384 rs9471438    
H1   T T 0.496 0.598 0.0179 
H2   C C 0.388 0.278 0.0062 
JAG2        
   rs2056860 rs1022431    
H3   T A 0.125 0.061 0.0069 
PVRL2        
   rs519113 rs2075642    
H2   G G 0.178 0.270 0.0125 






The most significant associations with CL/P in the MTHFR gene were found for 
common core (H1) haplotypes such as SNP 1-2-3 CTA (P = 0.0038), SNP 2-3 
TA (P = 0.0016), and SNP 1-3 CA (P = 0.0045), which were all associated with 
a higher risk of CL/P. The second most frequent (H2) haplotypes, such as SNP 
1-2-3 TGG (P = 0.0044), SNP 1-2 TG (P = 0.0030), SNP 3-4 GC (P = 0.0030), 
SNP 1-3 TG (P = 0.0036), and SNP 1-4 TC (P = 0.0029), were associated with 
a lower risk of CL/P. The strongest signals of haplotype-phenotype association 
in other candidate loci were found for MSX1 H2 TG (P = 0.0026), PVRL2 H3 
CA (P = 0.0054), BCL3 H3 CATA (P = 0.0071), EDN1 H2 CC (P = 0.0062), 
and JAG2 H3 TA (P = 0.0069) haplotypes, which were associated with a higher 
risk of CL/P, whereas the MSX1 H1 CA haplotype (with the lowest P-value of  
7 × 10–4), was associated with a lower risk of CL/P. The P-values obtained from 
haplotype-based association analysis performed with markers in MTHFR, 
BCL3, EDN1, and JAG2 were lower than analyses using individual SNPs. 
 
 
3. Genes contributing to the risk  
of nonsyndromic CP in Estonia 
We genotyped 630 tag SNPs in 40 candidate genes related to orofacial clefting 
in 53 patients with nonsyndromic CP and 205 unrelated controls from the 
Estonian population. Table 9 presents all markers with allelic association test P-
values of < 0.05 in the CP case-control sample.  
In the case-control analysis of the CP phenotype, 37 polymorphisms in 19 
genes displayed nominal evidence of association in our study sample.  
The most significant association with CP in the Estonian sample was found 
for SNP rs11624283 (P = 0.0016) in the JAG2 gene, SNPs rs615098 (P = 
0.0018) and rs629946 (P = 0.0027) in the MMP3 gene, and rs328149 in the 
LOXHD1 gene within ‘OFC11’ linkage region on Chr 18 (P = 0.0026). More 
SNPs of possible interest, rs1106514 in the MSX1 and rs33992 in the FGF1 







































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































4. Genes contributing to the risk  
of nonsyndromic CL/P in Baltic countries 
Five hundred and eighty-seven tag SNPs in 40 candidate loci related to 
orofacial clefting were genotyped in 300 CL/P patients and 606 unrelated 
healthy controls from Estonian, Latvian, and Lithuanian populations. The 
average genotype call rate for these SNPs was 99.1%. Genotype distributions 
among the study groups were in a Hardy-Weinberg equilibrium. The genomic 
control inflation factor (GC) was 1.008 for the entire dataset.  
All markers with allelic association test P-values below 0.05 (before 
correction for multiple testing) in the CL/P case-control sample are presented in 
Table 10. Thirty-three polymorphisms in 16 genes reached the nominal signi-
ficance level. The strongest association with CL/P was found for SNP rs34010, 
which is located in intron 2 of the fibroblast growth factor 1 (FGF1) gene, 
where the T allele was associated with a decreased risk (OR = 0.689; 95% CI = 
0.559–0.849; P = 4.56 × 10–4). The WNT9B rs4968282 minor allele G and the 
FOXE1 rs7860144 minor allele A were both associated with decreased risk of 
CL/P (OR = 0.688; 95% CI = 0.548–0.865; P = 0.0013; and OR = 0.723, 95% 
CI = 0.589–0.889, P = 0.0021; respectively). Association with rs34010 did 
withstand correction for multiple testing after dividing by the number of 
independent SNPs, taken to be equal to the number of haploblocks (N = 82) 
within candidate genes (Pcorr = 0.037) assuming that SNPs in one haploblock are 
not independent. The SNPs rs1907998 and rs6446693, both located 5’ of MSX1, 
were associated with CL/P under the assumption of the dominant model of 
inheritance (P = 3.97 × 10–4 and 5.84 × 10–4, respectively). Ten markers reached 
the 1% significance level, revealing FOXE1, TIMP2, PVRL2, and MMP13 
genes as additional loci of interest (Table 10).  
Stratification of our case-control sample according to sex showed no 
evidence for a sex-specific component in the association between CL/P and the 
10 markers with the strongest association signals (P < 0.01). The genotype 




















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































LD and haplotype analysis were performed with the whole dataset (CL/P 
patients and controls, N = 906). Eighty-two haplotype blocks were described in 
selected regions. Case-control analysis was performed for haplotypes 
constructed from SNPs within LD blocks, and the sliding-window approach 
was applied. Two haplotypes in FGF1 reached P<0.001, and several haplotypes 














 rs34002 rs250092 rs34010 rs250103    
H2 T G T A 0.288 0.349 0.00921 
H1 T G T * 0.308 0.391  5.42×10–4 
H4 T G G * 0.173 0.121 0.00274 
H2 * G T A 0.288 0.349 0.00914 
H2 * G T * 0.309 0.393 5.01×10–4 
H2 * * T A 0.287 0.349 0.00794 
F0XE1 
 rs10984009 rs973473 rs874004 rs7860144    
H1 G G G G 0.515 0.442 0.00402 
H2 G T C A 0.263 0.332 0.00303 
H1 G G G * 0.510 0.437 0.00318 
H2 G T C * 0.261 0.330 0.00286 
H1 * G G G 0.508 0.438 0.00495 
H2 * T C A 0.263 0.328 0.00468 
H1 G G * * 0.688 0.605 0.00101 
H2 G T * * 0.259 0.330 0.00311 
H1 * G G * 0.509 0.438 0.00421 
H2 * T C * 0.263 0.329 0.00414 
H1 * * G G 0.508 0.437 0.00472 
H2 * * C A 0.323 0.402 0.00120 
TIMP2 
 rs4789936 rs7211674 rs7502916 rs6501266    
H1 C A A T 0.407 0.478 0.00518 
H1 C A A * 0.402 0.480 0.00168 
H1 * A A T 0.409 0.474 0.00886 
H1 * * A T 0.425 0.496 0.00436 
H2 * * C C 0.481 0.415 0.00892 
 
a Likelihood ratio test for SNP1-3 sliding-window block haplotype effect: 2= 16.47  
(3 df); P = 0.0009 
b Likelihood ratio test for SNP1-3 sliding-window block haplotype effect: 2= 14.55  
(3 df); P = 0.0022 
c Likelihood ratio test for SNP1-3 sliding-window block haplotype effect: 2= 13.69  
(5 df); P = 0.018 
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Table 11 presents the results from haplotype-based association analysis within 
LD blocks identified at the FGF1, FOXE1, and TIMP2 loci for sliding windows 




Table 12. Case-control association analysis of haplotypes in four candidate genes 
 





 rs17603901 rs4968282 rs1105127    
H1 C A * 0.776 0.705 0.00134a 
H2 * G G 0.223 0.294 0.00155 
MMP9 
 rs13038175 rs6094237 rs17576    
H2 G A A 0.451 0.387 0.00969 
PVRL2 
 rs519113 rs2075642 *    
H3 G G * 0.188 0.251 0.00260 
LHX8 
 rs17565565 rs6593568 *    
H1 C A * 0.077 0.046 0.00610 
 
aLikelihood ratio test for SNP1-2 sliding-window block haplotype effect: 2 = 11.55  
(2 df); P = 0.0031 
 
 
Table 12 shows the results from haplotype-phenotype association analysis for 
common haplotypes with P  0.01 in the WNT9B, PVRL2, LHX8, and MMP9 
genes. 
The most significant associations with CL/P were found for the second most 
frequent haplotype rs250092/rs34010 GT and the most frequent haplotype 
rs34002/rs250092/rs34010 TGT in the FGF1 gene (P = 5.01 × 10–4 and 5.42 × 
10–4, respectively). Additionally, several common core haplotypes (H1) in 
FOXE1 were associated with a higher risk of CL/P, whereas the most frequent 
haplotypes in TIMP2 were associated with a lower risk of CL/P. The lowest P-
values were revealed for common core haplotypes GG in FOXE1 (P = 0.00101) 
and CAA in TIMP2 (P = 0.00168), and for the second most frequent (H2) 
haplotype CA in FOXE1 (P = 0.00120).  
The strongest signals of association in other candidate genes were found for 
WNT9B CA (P = 0.00134) and LHX8 CA (P = 0.00610) haplotypes, which were 
associated with an increased risk of CL/P. The WNT9B GG (P = 0.00155) and 





5. Genes contributing to the risk  
of nonsyndromic CP in Baltic countries 
We genotyped 591 tag SNPs in 40 candidate genes related to orofacial clefting 
in 104 patients with nonsyndromic CP and 606 unrelated controls from 
Estonian, Latvian and Lithuanian populations. The average genotype call rate 
for these SNPs was 99.25%. Genotype distributions among study groups were 
consistent with Hardy-Weinberg equilibrium. 
Table 13 presents all markers having allelic association test P-values below 
0.05 (before correction for multiple testing) in the CP case-control sample. 
Thirty-five polymorphisms in 17 genes displayed nominal evidence of asso-
ciation with the CP phenotype in our study sample, and 10 out of 35 SNPs had 
P-values less than 0.01.  
The most significant association with CP was found for SNP rs17389541, 
which is located ~8 kb upstream of the interferon regulatory factor 6 (IRF6) 
gene, where the T allele was associated with higher risk (OR = 1.726; 95% CI = 
1.263–2.358; P = 5.45 × 10–4). This SNP was significantly associated with CP 
under the assumption of the recessive model of inheritance (P = 9.87  10–6), 
and association remained significant after correcting for multiple testing.  
The A allele of the SNP rs1793949, located in an intron 44 of the collagen 
type 2 alpha 1 (COL2A1) gene, was associated with higher risk of CP (OR = 
1.596; 95% CI = 1.235–2.229; P = 7.26 × 10–4). Other markers of interest 
included the FGF2, MSX1, FGFR1, WNT3, and TIMP3 loci (Table 13). In the 
case of the MSX1, FGFR1, WNT3, and TIMP3 markers, a variant allele was 
associated with a risk effect, whereas the variant allele of the FGF2 SNP had a 
protective effect. 
There was no evidence of a sex-specific component in the association 
between CL/P and the nine markers with the best P-values. The genotype 
distributions in male and female cases were similar for these SNPs (Armitage’s 



































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































LD and haplotype analysis were performed with the whole dataset (CP cases 
and controls, N = 710). Case-control analysis was performed for haplotypes 
constructed from SNPs within LD blocks identified in the IRF6, COL2A1, 
COL11A2, MSX1, CLPTM1, BMP2, WNT3, MMP2, FGF1, FGF2, FGFR1, 
EDN1, JAG2, PVRL2, SKI, TIMP2, and TIMP3 genes. The sliding-window 
approach was applied. 
Table 14 presents the results from haplotype-based association analysis 
within LD blocks identified at the COL11A2 and COL2A1 loci for multiple 2- 
to 5-SNP haplotypes with a frequency of >5% in nonsyndromic CP patients and 
with P  0.01. The results from haplotype-phenotype association analysis for 
common haplotypes with P  0.01 in the CLPTM1, BMP2, WNT3, MMP2, 
FGFR1, and MSX1 genes are presented in Table 15. 
The most significant association with nonsyndromic CP was found for the 
second most frequent haplotype rs17389541/rs9430018 GT in the IRF6 gene 
(with frequencies of 0.353 in nonsyndromic CP cases and 0.233 in controls, 
respectively; P = 2.23 × 10–4). Additionally, multiple haplotypes in the 
COL11A2 and COL2A1 genes were associated with a higher risk of non-
syndromic CP. The lowest P-values in individual LD blocks were revealed for 
common core haplotypes CAA in COL2A1 block 2 (P = 5.76 × 10–4) and GC in 
COL11A2 block 2 (P = 9.85 × 10–4), and for the second most frequent (H2) 
haplotype GC in COL2A1 block 3 (P = 3.68 × 10–4). The most frequent (H1) 
haplotypes in COL2A1 block 3, such as GG (P = 0.0047) and GGA (P = 
0.0058), and haplotype CG in COL2A1 block 2 (P = 0.0062) were associated 
with a lower risk of nonsyndromic CP.  
The strongest signals of haplotype-phenotype association in other candidate 
loci were found for WNT3 H2 TGA (P = 0.0035) and CLPTM1 H2 TTC (P = 
0.0045) haplotypes, which were associated with a higher risk of CP, whereas 
the FGFR1 H3 CGG haplotype (P = 0.0040) was associated with a lower risk of 
CP. The P-values obtained from haplotype-based association analyses per-
formed with IRF6, COL11A2, COL2A1, CLPTM1, WNT3, BMP2, and MMP2 















































































































































































































































































































































































































































































































































































































































































































































































































Table 15. Haplotype-phenotype association analysis in six candidate genes 
 





 rs5127 rs10413089 rs3760629    
H2 T T C 0.301 0.212 0.0045 
WNT3 
 rs199497 rs199496 rs11658976    
H2 T G A 0.443 0.339 0.0035 
 rs11653738 rs3933652 rs3933653    
H2 C C C 0.407 0.314 0.0087 
BMP2 
 rs7270163 rs1005464 rs235770    
H4 G G C 0.084 0.152 0.0094 
MMP2 
 rs837533 rs837535 rs12924764    
H2 A A A 0.318 0.232 0.0072 
TIMP3 
       
H2 T A G 0.413 0.317 0.0065 
H2 T A * 0.412 0.317 0.0077 
FGFR1 
 rs7012413 rs6996321 rs7829058    
H3 C G G 0.156 0.249 0.0040 
H1 C * G 0.517 0.616 0.0073 
H3 C * C 0.157 0.095 0.0072 
MSX1 
 rs1106514 rs12501827 rs12498543    







1. Surveillance system 
In Estonia, patients with clefts are treated at the Tartu University Hospital and 
in the North Estonian Medical Centre. There is no exclusive database for 
Estonian patients with clefts and therefore it is not possible to include all of the 
cleft cases in the study. Registration and classification of congenital anomalies 
in general, and common OCs in particular, is of paramount importance in 




For Estonia, we can use only the prevalence findings by Lõvi-Kalnin (1996), 
conducted between 1970 and 1980. On the basis of the Lõvi-Kalnin study 
(1996), the rate of occurrence of clefts in Estonia would be 1 case per 777 live 
births. Therefore, the only way to estimate the number of children affected by 
clefts is to use the pre-existing information from previous visits to maxillofacial 
surgeons. Today the occurrence rate of OC is under observation and we cannot 
report the prevalence of OC in Estonia. 
Different ethnic groups have different occurrence rates of different cleft ty-
pes. Geographical trends for CL/P and other congenital anomalies have been re-
ported in many different studies (EUROCAT http:// www.eurocat.ulster.ac.uk/ 
pubdata/Publications.html and IBCDMS http://www.icbd.org/). The ethnic 
differences in facial shape are well recognized (Farkas et al., 2005). It has been 
suggested that liability to cleft might be related to facial shape (Pashayan and 
Fraser, 1971; Fraser, 1976) on the basis that parents of children with CL/P have 
greater bizygomatic width, underdeveloped maxilla and a thinner upper lip than 
the general population. Unfortunately, good studies comparing cephalometric 
measures among the European populations are lacking. Facial shape seems to 
reflect climate (Harvati and Weaver, 2006). Weninger (1979) found, in two 
quite different geographical regions (Mozambique and Hierro, Canaries), that 
the maximum head breadth was larger in localities at a higher altitude or/and 
with a colder climate, than in localities with milder climates. 
The differences in cleft prevalence may be related to sun exposure, and 
studies based on latitude (Grant, 2008; Holick, 2008; Grant and Mohr, 2009) 
can explain the role of solar UVB and dietary factors in the etiology of 
malformations (Calzolari et al., 2007). The study by Engström (1982) shows 
that craniofacial morphology in the rat is influenced by low calcium and low 
vitamin D. Calzolari et al. (2007) found a positive correlation between isolated 






3. Cleft proportion 
In the present study, CL formed 19% of all clefts, CLP formed 42%, and CP 
39%. Fogh-Andersen (1942) was the first to emphasize the proportions of 
occurrence of different cleft types in the Caucasian race: CL: CLP: CP – 1:2:1. 
The prevalence of CP varies significantly in Europe, not only between registries 
but also within countries (Calzolari et al., 2007). A recent study from The 
Netherlands by Luijsterburg and Vermeij-Keers (2011) reported the following 
cleft proportions: CL (28%): CLP (39%): CP (33%). One of the findings of the 
present study was a high occurrence rate of CP: CL (19%): CLP (42%): CP 
(39%) – 1:2:2, which is similar to the studies conducted in Finland and Sweden 
(Rintala, 1986; Hagberg et al., 1998). The reasons for this finding need further 
research. Different ethnic groups have different occurrence proportions of 
different cleft types, and the proportion of isolated CP in general is significantly 
smaller than the total number of clefts (Natsume and Kawai, 1986). 
Across all unilateral CLP and CL, the left side of the face is involved in 2/3 
of cases (Wyszynski et al., 1996; Fraser, 1970). According to the present study, 
the left side of the face was affected 2.2 times more frequently than the right 
side. No definite explanation for the difference in left- and right-side occur-
rences is given in the literature. Johnston and Brown (1980) have suggested that 
blood vessels supplying the right side of the fetal head leave the aortic arch 
closer to the heart and may be better perfused by blood than those on the left 
side. 
 
4. Gender ratio 
Among Caucasians, men have CLP twice as frequently as women, while CP is 
more common among women than men (Wyszynski et al., 1996; Calzolari et 
al., 2007). It also became evident in the present study that significantly more 
boys were born with CLP (the ratio with girls is 2:1), and girls had CP 1.5 times 
more frequently than boys. Boys also have more severe diagnoses – there are 
more CLP patients than CL patients and there are also more bilateral than unila-
teral cases (Fraser, 1970). According to this study, boys have CLP 2.2 times 
more frequently than CL, but there are fewer bilateral cases than left-side cases. 
There is no definite scientific explanation for the differences in clefts, between 
sexes. One reason given is that the development of clefts occurs at different 
stages of development in male and female fetuses in the critical stage (Burdi 




Several studies have shown that the birthweight of children with clefts is similar 
to the birthweight of children without clefts (Conway, 1966), which was also 
confirmed by the present study. But the majority of studies demonstrated that 
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children with CLP presented smaller body dimensions when compared with 
controls (Marques, 2009; Luijsterburg and Vermeij-Keers, 2011). 
 
 
6. Parents’ age 
During the last 20 years, maternal and paternal ages have increased. Some 
malformations are clearly associated with older maternal age, but the effect of 
paternal older age is less certain. Increased maternal age is a risk factor for both 
chromosomal (Hook, 1981) and non-chromosomal abnormalities (Hollier et al., 
2000). 
In the case of Estonian children with clefts, the mother’s age exceeded 30 
years in 25% of cases and the father’s age exceeded 30 years in 33% of cases. 
Both parents were older than 30 years in 20% of cases. Half of the mothers 
were between the age of 20 and 30, and 2.6% were older than 40 years.  
An association between advanced maternal age and the occurrence of any 
type of OC has been found in several studies (Saxen, 1974; Womersly and 
Stone, 1987; Shaw et al., 1991), but not in all studies (Khoury et al., 1983; Baird 
et al., 1994; Vieira et al., 2002; González et al., 2008). In this study, no maternal 
age effect could be observed. Only a few population-based studies were 
conducted according to the recommendations of the International Consortium 
for Oral Clefts Genetics (Mitchell et al., 2002), distinguishing between CL/P 
and CP only, and excluding cases with associated anomalies. A study by Bille 
et al. (2005), using the population-based Danish Facial Cleft Database, found 
that the influence of maternal and paternal ages on the risk of CL/P increases 
with the advancing age of the other parent, and that the influence vanishes if the 
other parent is young. In contrast, the risk of having a child with CP is 
influenced only by the father’s age, not the mother’s age (Bille et al., 2005). 
Ascertaining whether greater parental age is associated with OC is not only of 
interest for clarifying the etiology of OC, but is also important from a biological 
and public-health point of view.  
 
 
7. Specific exposures 
In the present data, over a third of mothers of children with clefts (36%) expe-
rienced psychological stress during pregnancy. The main stressors described 
were problems in the family. However, stress is an important factor in the 
occurrence of clefts (Fraser, 1970). One fifth of mothers did hard physical work 
during pregnancy (field work, stock raising) or experienced physical trauma 
(struck by an animal, domestic violence). Forty five percent of mothers had 
previously undergone at least one medical abortion and 23% had undergone 
more than one. One third of mothers (34%) had an exposure to some chemical 
factor: one fifth (22%) had been exposed to teratogenic toxic substances 
(fertilizers, various chemicals, medications), 15% had hormonal disorders 
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during pregnancy (toxicosis during the first trimester or diseases such as 
diabetes or thyreotoxicosis). 
There is little information regarding the temporal sequence between expo-
sure and the outcome of the environmental risk factors, and a dose-response 
relationship cannot be demonstrated. Not enough information is available to 
draw any conclusions about the role of these exposures and the risk of oral cleft 
formation. Many risk factors and mechanisms have been described in the 
literature for OC (Wyszynski and Beaty, 1996). 
 
 
8. Candidate gene studies 
Candidate gene-based association studies have emerged as a useful tool in the 
investigation of the genetic component of multifactorial diseases, such as CL/P, 
as a way to focus on certain regions of interest in the human genome.  
Some authors have argued that population-based case-control designs in 
which candidate genes are used are more suitable than a case-parent design in 
assessing the effects of risk factors – a crucial step in disease prevention and 
health promotion (Khoury, 1999). However, family-based studies may still be 
useful if population stratification is present. The case-parent trio design avoids 
concerns about spurious results due to population stratification within the 
sample, primarily because the observed case is always compared with ethnically 
matched ‘pseudocontrols’ (parents) (Beaty et al., 2002). 
Results from genome scans suggest that several regions may contain genes 
predisposing to the development of nonsyndromic clefts. On the basis of 
multiple reports on the association between markers and haplotypes in various 
genes and OC, we analyzed the role of 18 candidate genes in the Estonian 
sample for a possible association with CL/P, and 26 SNPs in 9 genes showed 
nominal P-values less than 0.05. The most significant associations with CL/P 
were found for SNPs in MSX1, MTHFR, and PVRL2, including several common 
haplotypes in the MTHFR and MSX1 genes. The association with SNP 
rs6446693 in the MSX1 gene region remained statistically significant after 
correcting for multiple testing. 
In the Estonian CP sample, we conducted a study to investigate the role of 
40 candidate genes in predisposition to nonsyndromic CP. Six hundred and 
thirty tag SNPs were genotyped in a sample of 53 CP patients and 205 controls. 
The strongest associations with nonsyndromic CP were found for JAG2, 
MMP3, FGF1, MSX1 and in the LOXHD1 gene within the ‘OFC11’ linkage 
region on chromosome 18. 
Considering the small sample size of our patient group, we must emphasize 
that our study carries the risk of false-positive findings as a result of the large 
number of comparisons performed. Conversely, we cannot exclude the possi-
bility that a modest effect of polymorphisms or haplotypes in disease predis-
position may become apparent in a larger sample. 
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In a follow-up study including neighbouring populations, we genotyped 587 
tag SNPs in 40 candidate gene regions, to determine their role in the etiology of 
CL/P. We genotyped 591 tag SNPs in 40 candidate genes related to orofacial 
clefting in 104 patients with nonsyndromic CP and 606 unrelated controls in a 
new clefting sample representing three populations from the Baltic region – 
Estonians, Latvians and Lithuanians. As they share the same geographic origin, 
the genetic relatedness of Estonians, Latvians and Lithuanians has been recently 
confirmed using the principal component analysis, according to the pairwise 
inflation factor  and pairwise Fst values between samples (Nelis et al., 2009). 
We found no evidence of systematic bias due to population stratification as 
indicated by the genomic control inflation factor (GC1) and the quantile-
quantile plots which confirmed the high degree of homogeneity between all 
three population samples, allowing us to summarize the data of three Baltic 
countries to increase the study power.  
Results from this association analysis suggest that several regions may 
contain genes predisposing to the development of CL/P. Among the 40 
candidate genes analyzed for an association with CL/P, 33 SNPs in 16 genes 
reached the 5% significance level. The most significant associations were found 
for SNPs in the FGF1, FOXE1 and WNT9B genes. The strongest evidence of 
association was found for SNP rs34010 in the FGF1 gene.  
Among the 40 candidate genes analyzed for a possible association with 
nonsyndromic CP, 35 SNPs in 17 genes showed nominal P-values less than 
0.05. The strongest evidence of association was found for SNPs rs17389541 in 
the IRF6 gene and rs1793949 in COL2A1. These associations were not 
significant after Bonferroni correction, but remained significant after correction 




Methylenetetrahydrofolate reductase (MTHFR) is an important enzyme 
involved in folate metabolism. Many studies have been undertaken to verify the 
association between two functional polymorphisms in the MTHFR gene –  
677 C>T (rs1801133, c.665C>T, p. Ala222Val) and 1298 A>C (rs1801131, 
c.1286A>C, p. Glu429Ala) – and increased risk of CL/P malformation. 
However, these studies have provided inconsistent results due to differences in 
the studied populations as a result of their diverse genetic backgrounds and 
exposure to varying environmental factors. It has been proposed that low 
periconceptional folate intake increases the risk of CL/P in offspring, and this 
risk is even more pronounced in mothers with MTHFR 677TT or 1298CC 
genotypes (van Rooij et al., 2003).  
In our study, the MTHFR SNPs rs1994798, rs1476413, and rs1801131 (1298 
A>C; c.1286A>C, p. Glu429Ala ), together with multiple risk and protective 
haplotypes within the same LD block, showed evidence of association with 
CL/P in the Estonian study sample. It has been suggested that rs1801131 is not 
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directly connected to the risk of developing CL/P, but this may be due to near 
complete LD between 1298 A>C (rs1801131, c.1286A>C, p. Glu429Ala) and 
677 C>T (rs1801133, c.665C>T, p. Ala222Val) or disequilibrium with another 
mutation responsible for the malformation (Pezzetti et al., 2004). Confirmation 
of an association or linkage between 1298 A>C (rs1801131, c.1286A>C, p. 
Glu429Ala) and CL/P risk, either separately or in combination with 677 C>T 
(rs1801133, c.665C>T, p. Ala222Val), has not been found (Beaty et al., 2002; 
van Rooij et al., 2003). An association between 1298 A>C (rs1801131, 
c.1286A>C, p. Glu429Ala) and CP cases or mothers was not found in a 
previous study (Jugessur et al., 2003b). Likewise, the 1298 A>C (rs1801131, 
c.1286A>C, p. Glu429Ala) variant was not found to be a risk factor for CL/P or 
CP (Mills et al., 2008). In conclusion, it appears likely that 1298 A>C 
(rs1801131, c.1286A>C, p. Glu429Ala) and the two other described poly-
morphisms are not independent risk factors for CL/P, but our data does not 




MSX1 has been a plausible candidate gene for clefting. The complete se-
quencing of the MSX1 gene demonstrated that point mutations in this gene 
appear to contribute to approximately 2% of all CL/P cases (Jezewski et al., 
2003). Association studies of CL/P (Lidral et al., 1998; Beaty et al., 2002; 
Vieira et al., 2003; Fallin et al., 2003) and CP (Lidral et al., 1998) have 
supported a role for MSX1 in nonsyndromic clefting in different populations. In 
the Estonian sample from our study, the most significant association with CL/P 
among all screened candidate genes was found for SNP rs6446693 in the MSX1 
region. The same SNP was associated with CL/P in the Baltic sample. In the 
Estonian and Baltic CP samples, SNP rs1106514 in the MSX1 gene was 
associated with nonsyndromic CP. Case-control studies have reported both 
positive (Lidral et al., 1998; van den Boogaard et al., 2000; Blanco et al., 2001) 
as well as negative results. Research data have supported interaction between 
environmental factors and MSX1. The risk of CL/P and CP, related to maternal 
cigarette smoking and alcohol consumption during pregnancy, increases due to 
the interaction of such exposure and specific allelic variants at the MSX1 gene 
(Romitti et al., 1999). Taken together with several other SNPs and haplotypes 
demonstrating an association with CL/P and CP, it can be concluded that we 
have successfully replicated previous findings, showing an association between 
MSX1 variants and CL/P and CP. 
 
 
8.3. OFC3 (locus 19q13)  
Multiple lines of evidence support the role of one or more genes in the OFC3 
region (Chromosome19q13) in clefting. PVRL2, located on 19q13, has recently 
been added to the list of candidate genes hypothesized to play a role in the 
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etiology of CL/P (Lidral and Murray, 2004). Recent data suggest that both rare 
and common variants in PVRL1, closely related to PVRL2, make a minor 
contribution to nonsyndromic CL/P in multiple populations (Avila et al., 2006; 
Scapoli et al., 2006). An association study involving five populations did not 
find an association between CL/P and mutations in the PVRL2 gene. However, 
a significant association with an allelic variant in PVR, a gene homologous to 
PVRL2, was found (Warrington et al., 2006). In the same study, 16 PVRL2 
variants – 5 common and 11 rare – were identified in cleft patients. We found 
an association between SNPs rs 519113 and rs2075642 in PVRL2 and CL/P.  
BCL3, a proto-oncogene that encodes a transcription factor involved in cell 
cycle regulation, has been suggested as a candidate gene for CL/P (Gaspar et 
al., 2002; Park et al., 2009). The BCL3 gene has been associated with OC in 
some association studies (Gaspar et al., 2002; Park et al., 2009), but not others 
(Fujita et al., 2004; Suazo et al., 2005). A possible reason for these conflicting 
results is that the susceptibility loci may have different contributions in different 
populations. 
We described associations between CL/P and BCL3 markers and haplotypes 
in the Estonian sample, including SNP rs8100239, for which excess maternal 
transmission has been previously reported in CL/P cases, probably reflecting an 
imprinting effect or a maternal genotype effect (Park et al., 2009). 
A study of a multiplex family in which CL/P segregated with a balanced 
translocation between 2q11.2 and 19q13.3 suggested that the cleft lip and palate 
transmembrane 1 (CLPTM1) gene, localized to this breakpoint, might play a 
role in clefting (Yoshiura et al., 1998). Our independent sample showed evi-
dence of association, suggesting the involvement of CLPTM1 in nonsyndromic 
CP etiology. In addition, further evidence that the 19q13 region contributes to 
isolated clefting in heterogeneous populations of European descent has been 
found (Warrington et al., 2006).  
Our work provides further evidence that a 19q13 locus contributes to 
nonsyndromic clefting in heterogeneous populations of European descent. A 
previous meta-analysis of 13 genome scans, combining datasets from multiple 
populations in a linkage analysis to detect candidate loci for CL/P, suggested a 




Our study is the first to demonstrate an association between endothelin 1 
(EDN1) gene variants and haplotypes and CL/P. EDN1 maps to the chromo-
somal region of the OFC1 locus (chromosome 6p24-p23) and has been 
suggested as a candidate gene for CL/P on the basis of the results of linkage 
studies conducted in populations of different ancestries (Moreno et al., 2004). 
Mostly borderline significant association signals combined with evidence 
presented from epistasis analysis suggest that gene-gene interaction(s) could be 
a possible mechanism for how EDN1 exerts its effect as a locus contributing to 
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CL/P. Four SNPs from the Estonian CL/P sample (rs6912834, rs4714384, 
rs6906760, rs9471438), and rs16872612 from the Baltic sample, showed 
associations with CL/P. 
There is no information how EDN1 may influence the development of OC. 
As EDN1 is involved in neural crest development this may be the pathway that 
plays some role; or gene-gene interaction(s) could be a possible mechanism for 




The JAG2 gene encodes a ligand for the Notch family of transmembrane 
receptors, which are involved in an essential signalling mechanism required for 
normal palate development (Casey et al., 2006). In recent family-based 
association studies, evidence for JAG2 involvement in CL/P was obtained from 
haplotype analyses using global tests and single haplotype association tests 
(Vieira et al., 2005; Scapoli et al., 2008). Interestingly, the most significant data 
in both studies were obtained with haplotypes that include the nonsynonymous 
polymorphism, rs1057744. Recently, it has been demonstrated that IRF6 and 
Jagged2 function in convergent molecular pathways during oral epithelial 
differentiation and that this integrated signalling is essential for the control of 
palatal adhesion and fusion competence (Richardson et al., 2009). 
In our study, we found evidence of an allelic association between rs1022431 
and CL/P, where allele A was associated with a higher risk of CL/P. This was 
supported by analysis of haplotypes including this polymorphism. Among all 
candidate genes screened in this study, the most significant association 
observed within the Estonian CP sample (P = 0.0016) was for rs11624283 in 
the JAG2 gene, and the most significant association observed in the Baltic CP 
sample (P = 0.0318) was for rs10134946. These results indicate that JAG2 




IRF6 is one of the CL/P candidate genes with the most accordant results across 
studies (Vieira, 2008). The most common syndromic form of orofacial clefts is 
Van der Woude syndrome (VWS), an autosomal dominant disorder charac-
terized by the presence of CL/P or CP and/or lower-lip pits. VWS is caused by 
mutations in the IRF6 gene, which belongs to a family of transcription factors 
that share a highly conserved winged-helix DNA-binding domain and a less 
conserved protein interaction domain (Kondo et al., 2002). IRF6 is expressed in 
the medial edge epithelia of the palatal shelves immediately prior to and during 
fusion (Knight et al., 2006). Interestingly, VWS is an example of an orofacial 
syndrome in which cases of CP and CL/P can occur in the same pedigree, 
suggesting that IRF6 is probably involved in the fusion process that occurs in 
both primary and secondary palatogenesis. However, IRF6 mutations are rare in 
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families with nonsyndromic orofacial clefts (Jehee et al., 2009). Recently, it has 
been demonstrated that IRF6 is essential for oral epithelial differentiation and 
that IRF6 plays a key role in the control of palatal adhesion and fusion 
competence (Richardson et al., 2009). In the present study, from the Baltic CP 
sample, the IRF6 SNP rs17389541 showed evidence of association, supported 
by analysis of haplotypes including this polymorphism, which is a novel 
implication of IRF6 in nonsyndromic CP susceptibility. HapMap data from the 
CEU reference sample indicate that rs17389541 is not in strong LD with the 
common polymorphism IRF6 rs642961 (r2 = 0.057) that was significantly 
associated with nonsyndromic CL/P and particularly with CL in Europeans, but 
not with CP (Rahimov et al., 2008). It is likely that association between 
common variants in the IRF6 locus and the risk of nonsyndromic CP can be 
identified in other European populations and that the IRF6 locus represents an 
important genetic modifier for this multifactorial malformation.  
In our Baltic CL/P sample, we could not demonstrate convincing evidence of 
an association between CL/P and variants in IRF6. 
 
 
8.7. FGF and FGFR  
Several members of the FGF and FGFR families are expressed during cranio-
facial development and can, rarely, harbour mutations that result in human 
clefting syndromes. In a study of Kallmann syndrome patients, cleft palate and 
dental agenesis were exclusively found associated with FGFR1 loss-of-function 
mutations (Albuisson et al., 2005). Animal models also support the involvement 
of FGFs and FGFRs in the pathogenesis of oral clefting; for example, FGFR1 
hypomorphic mice have CP (Trokovic et al., 2003). The FGF signalling 
pathway is known to play an important role in craniofacial development, and 
perturbation of the FGF signal is critical to palatogenesis (Nie et al., 2006). A 
systematic analysis of genes encoding different FGF proteins and their receptors 
has highlighted the importance for FGF signalling in nonsyndromic CL/P, and it 
was suggested that impaired FGF signalling may contribute to 3–5% of CL/P 
(Riley et al., 2007). In addition, it has been suggested that FGF pathway is 
involved in interactions with environmental risk factors for CL/P (Pauws and 
Stanier, 2007). Recently, FGF12 haplotypes were shown to be significantly 
associated with CL/P in two Scandinavian samples (Jugessur et al., 2009). In 
the present study, the FGF1 SNP rs34010 showed evidence of association in the 
Baltic sample and FGF1 SNP rs33992 in the Estonian nonsyndromic CP 
sample, which is a novel implication of FGF1 in CL/P susceptibility. Our 
results give additional evidence that disruptions in the FGF signalling pathway 
contribute to the pathogenesis of CL/P, also suggesting that association between 
common variants in the FGF1 locus and the risk of CL/P can be found in other 
European populations.  
We found associations between nonsyndromic CP and SNPs rs7829058 in 
FGFR1 in the Baltic sample and rs308434 in the FGF2 gene in the Baltic and 
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Estonian samples. SNP rs08441 was associated with nonsyndromic CP in the 
Estonian sample. Association with FGFR1 was supported by haplotype 
analysis.  
Recently, borderline significant association between SNPs in several FGF/ 
FGFR genes (including FGFR1) and nonsyndromic CL/P was demonstrated, 
and it was suggested that impaired FGF signalling may contribute to non-
syndromic CL/P (Riley et al., 2007). FGFR1 encodes a transmembrane 
receptor, tyrosine kinase, that transduces signals from secreted FGFs, and 
insufficient FGFR1-mediated signalling during embryonic development may 
have an impact on palatogenesis in humans and/or mice. It can be concluded 
that disruptions in the FGF signalling pathway might contribute to non-




The forkhead box E1 gene (FOXE1) is a member of a transcription factor 
family that contains a DNA-binding forkhead domain and regulates diverse 
developmental processes in eukaryotes. Foxe1 is expressed in the secondary 
palate epithelium in humans at embryonic week 11, and the specific expression 
pattern of Foxe1 at the point of fusion between the medial nasal and maxillary 
processes strongly suggests FOXE1 as an important player in primary palato-
genesis (Trueba et al., 2005; Moreno et al., 2009). Twelve coding variants – 
missense or silent – in FOXE1 have been described as rare causes of non-
syndromic CL/P (Vieira et al., 2005). Recent studies have implicated SNPs 
and/or haplotypes clustering in or near FOXE1 as highly significant risk factors 
of CL/P, and the described association signals indicated the presence of causal 
mutations in nearby non-coding regions that regulate FOXE1 expression 
(Jugessur et al., 2009; Marazita et al., 2009; Moreno et al., 2009). The three 
associated SNPs from the current study’s Baltic CL/P sample – rs7860144, 
rs874004 and rs973473 – are located within a 70 kb haplotype block including 
SNPs rs3758249 and rs4460498, which were the most significantly associated 
with CL/P in multiple populations (Moreno et al., 2009). Our results support a 
substantial role for FOXE1 in the development of CL/P and it’s likely that the 




8.9. Wnt signalling pathway genes  
Wnt signalling pathway genes are involved in craniofacial development and 
upper lip fusion and are therefore plausible candidates for an etiological role in 
nonsyndromic clefting. Wnt expression is observed in the upper lip and primary 
and secondary palates and Wnt signalling mediates regional specification in the 
vertebrate face (Brugmann et al., 2007). In our Baltic CL/P sample, the WNT9B 
SNP rs4968282 showed evidence of association with CL/P. WNT9B lies 32 kb 
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telomeric from the start codon of WNT3, which is required at the earliest stages 
of human limb formation and for craniofacial morphogenesis. Furthermore, 
both Wnt9b and Wnt3 are mapped in the clf1 locus in clefting-susceptible mice 
(Juriloff et al., 2005). The gene alterations outside the WNT9B coding sequence 
are expected to cause reduced WNT9B gene or protein function in CL/P cases, 
and WNT9B has been suggested as a strong candidate gene for CL/P (Juriloff et 
al., 2006). The SNP rs197915 downstream of WNT9B showed association with 
CL/P in the European American sample subgroup having a positive family 
history, whereas the strongest association signals in the entire dataset were 
reported for SNPs in WNT3A, WNT5A, and WNT11 (Chiquet et al., 2008). In 
contrast, association with rs197915 was not replicated in the Brazilian CL/P 
sample of Caucasian ancestry, whereas significant association with WNT3 
rs142167 was found (Menezes et al., 2010). In our study, the WNT3 SNP 
rs11653738 in the Baltic nonsyndromic CP sample and SNP rs916888 in the 
Estonian nonsyndromic CP sample, showed evidence of association with 
nonsyndromic CP. WNT3, a human homolog of the Drosophila wingless gene, 
encodes a member of the WNT family known to play key roles in embryonic 
development, and WNT3 is required at the earliest stages of human limb 
formation and for craniofacial development. In a recent study, the strongest 
association signals were found between SNPs and haplotypes in WNT3A and 
nonsyndromic CL/P, as well as evidence of gene-gene interaction between 
WNT3 and WNT3A (Chiquet et al., 2008). These findings were extended in a 
Norwegian sample of nonsyndromic CP case-parent trios where a haplotype 
effect was reported for the WNT3A gene (Jugessur et al., 2009). 
Our data support an involvement of the WNT signalling pathway in 
orofacial development, also suggesting that the 17q21 locus, containing WNT9B 
and WNT3 genes, contributes to CL/P in populations of European descent. 
 
 
8.10. TIMPs and MMPs 
Matrix metalloproteinases (MMPs) have been shown to be expressed in the 
developing secondary palate, associated with the extracellular matrix (ECM) 
breakdown required for palatal fusion (Brown et al., 2002). MMPs are 
counteracted by the tissue inhibitors of metalloproteinases (TIMPs), which 
inhibit MMP activity and thereby reduce excessive proteolytic ECM degra-
dation (Verstappen and Von den Hoff, 2006). During embryonic craniofacial 
development, MMP and TIMP expression is temporally and spatially regulated 
to control tissue remodelling, and disruption of their balance can lead to 
occurrence of malformations, such as CL/P (Blavier et al., 2001). In our Baltic 
sample, associations with CL/P and CP were found for several SNPs and 
haplotypes in TIMP2, supporting initial findings in a Norwegian sample of 
CL/P case-parent trios where a haplotype effect was reported for the TIMP2 
gene (Jugessur et al., 2009). Our study provides evidence of the implication of 
MMP3 in the occurrence of nonsyndromic CP in the Estonian population. 
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Further independent studies in other populations with a substantially larger 
number of individuals should be conducted to verify and extend these results. 
The inactivation of MMPs by TIMP2 leads to a failure of palatal fusion in mice 
(Blavier et al., 2001). Therefore, strict regulation of MMP activity is necessary 
for a complete fusion of the palatal shelves, and an imbalance in favour of 
TIMP2 may increase the risk of CP (Verstappen and Von den Hoff, 2006). The 
link between CL/P risk and variants in MMP and TIMP genes seems to also 
rely on alterations in ECM homeostasis and functions.  
 
 
8.11. COL2A1 and COL11A2 
Mutations in genes coding for cartilage collagens II and XI (COL2A1, 
COL11A1 and COL11A2) cause syndromes that are often associated with 
Pierre-Robin sequence, cleft palate or micrognathia, but it seems possible that 
sequence variations in collagen II and XI genes may cause or predispose to 
nonsyndromic conditions in some instances (Melkoniemi et al., 2003). A 
variety of mutations in the COL2A1 gene have been identified in families with 
Stickler syndrome type 1 with systemic features involving Pierre-Robin 
sequence, severe myopia and/or vitreoretinal phenotype, and osteoarthritis in 
later life. This study presents the first report describing associations between 
nonsyndromic CP and several common SNPs, with the strongest association 
signals found for the intronic SNP rs1793949. In addition, our data showed an 
association between nonsyndromic CP and certain haplotypes in COL11A2, 
supporting recent findings describing the haplotype effect found for the 
COL11A2 gene in a Norwegian sample of nonsyndromic CP case-parent trios 
(Jugessur et al., 2009). Moreover, one of the chromosomal regions for clefting 
in mice encompasses the H2 locus, which is homologous to the human HLA 
locus on 6p21, and includes susceptibility for both corticosteroid-induced and 
vitamin A-enhanced CP (Murray, 1995). However, we cannot exclude the 
possibility that observed associations for COL11A2 could be explained by a 
limited number of unidentified Stickler syndrome type 3 patients in the study 
group. As these patients do not present ophthalmic abnormalities and the main 
conclusive features could be Robin sequence, cleft palate and osteoarthritis, this 




Mutations in the T-box transcription factor gene TBX22 are found in familial 
and sporadic patients with X-linked cleft palate and ankyloglossia (CPX), 
which is inherited as a semidominant X-linked disorder. The phenotypic va-
riability in CPX ranges from a mild submucous cleft palate to a severe, comp-
lete cleft of the secondary palate. In addition to familial CPX cases, mutations 
in TBX22 have been identified in approximately 5–8% of all patients with 
nonsyndromic CP, and TBX22 has been proposed to contribute significantly to 
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the prevalence of nonsyndromic CP across different populations (Marçano et 
al., 2004; Suphapeetiporn et al., 2007). In a recent study, a functional haplotype 
variant in the TBX22 promoter was significantly associated with CP and 
ankyloglossia (CPA), but association was not significant between cleft palate 
only (CPO) patients and controls (Pauws et al., 2009). Likewise, our results do 
not support an involvement of common TBX22 variants in nonsyndromic CP 
predisposition. This result is not unexpected, given the heterogeneous nature of 
nonsyndromic CP and its various confounding factors. 
Numerous candidate gene studies have failed to identify either major gene 
involvement or mutations exerting a major influence on the risk of developing 
nonsyndromic OC. The failure to pinpoint the molecular events that lead to 
clefting in humans most likely arises from insufficient knowledge of gene net-
works and the regulation of gene expression during palatal development. More-
over, it is becoming clear that oral clefts are caused by complex interactions 
between genetic and environmental variables, which may have different impacts 
in distinct populations. 
As reported previously, Estonians share a relatively common genetic back-
ground with the HapMap CEU reference population and several other European 
populations (Mueller et al., 2005; Montpetit et al., 2006). The genetic related-
ness of Estonians, Latvians and Lithuanians, sharing the same geographic 
origin, has been recently confirmed (Nelis et al., 2009). 
Recent GWA studies have reported several new susceptibility loci (2q21, 
8q24.21, 10q25.3, 13q31, 15q13 and 17q22 ) for CL/P in populations of Euro-
pean descent (Birnbaum et al., 2009; Mangold et al., 2010). None of the 40 
genes that we selected, before the era of GWA studies, for their potential 
contribution in clefting lies within the abovementioned chromosomal regions, 
therefore possible new candidate genes were not included in our selection and 
associated SNPs in given loci were not genotyped in the overall Baltic sample. 
However, in a recent independent study, the most significant SNP rs987525 at 
the 8q24.21 locus was replicated in Estonian and Lithuanian CL/P samples and 
association with 10q25.3 locus (rs7078160) was replicated in an Estonian 
sample only (Nikopensius et al., 2009; Nikopensius et al., 2010). The SNPs in 
four other loci from GWA studies were not replicated in our study.  
We acknowledge that a study design based on LD between markers and 
unobserved etiological variant(s) will have limited power to detect multiple rare 
variants (e.g. copy number variants) that could also be functionally relevant, 
and further studies are warranted to confirm reported associations. When in-
vestigating the association of single genes with the risk of a complex trait likely 
to be governed by a considerable number of genes, ORs are almost always low 
to moderate. This reflects that a specific phenotype results of a combination of 
different genes, contributing only a small effect, and environmental factors, so 
taking in consideration the epistasis and gene-environment interactions is 
appropriate to explain the remaining genetic risk to be identified for the non-




CLINICAL IMPORTANCE AND PRIMARY 
PREVENTION OF OROFACIAL CLEFTS 
Orofacial cleft etiology is heterogeneous. Individuals with OC may experience 
problems with feeding, speaking, hearing and social integration, which can be 
corrected to varying degrees by surgery, dental treatment, speech therapy and 
psychosocial intervention. Identification of risk factors for OC is the first step 
towards primary prevention. Large, collaborative studies are needed to elucidate 
environmental and genetic risk factors for orofacial clefts and interactions 
between them. The recent identification of genes that are likely to influence the 
risk of nonsyndromic OC, has an impact on genetic counselling in the future 
and clinical management. 
The genetic mechanisms underlying lip and palate development may be due 
to the disruption of important signalling pathways at various levels that are 
required for the formation of specific anatomical structures. The challenge is 
now to perform full-scale genome sequencing in order to identify genetic 
variants which are more likely to increase the susceptibility to OC. However, 
estimations of the total genetic contributions to the disease indicate that 
additional genetic factors involved in OC need to be identified, and both the 
functional effects of associated variants and the molecular mechanisms behind 
different pathways must still be ascertained. Further research using large, 
multicentre, collaborative studies is necessary to identify both genetic and 




A combination of epidemiological and clinical approaches may enhance our 
understanding of the cause and pathogenesis of congenital malformations and 
may be useful for public health, treatment, and preventive strategies. 
The main conclusions of our work are as follows: 
1.  The present study is the first to present an overview of patients with clefts 
treated in the Department of Oral and Maxillofacial Surgery of the Tartu 
University Hospital over the course of 90 years (1910–2000). During this 
period, 583 patients were recorded (251 females and 332 males; a sex ratio 
of 1:1.32 respectively).  
2.  Of the 583 patients with OC, 19% had CL, 39% had CP and 42% had CLP. We 
found a high occurrence rate of CP among all clefts (CL: CLP: CP – 1:2:2). The 
most common OC in boys was left-side CLP; in girls it was CP. The left side of 
the face was damaged 2.2 times more frequently than the right side. 
3.  Over a third of mothers of children with OC had experienced psychological 
stress during pregnancy, 45% of mothers had previously undergone at least 
one medical abortion, and 20% of mothers had been exposed to teratogenic 
toxic substances. The average birthweight of the children with OC was 
similar to the birthweight of children without clefts. An association between 
maternal age and the occurrence of OC could not be observed.  
4.  The results of this study suggest that several genes known to be involved in 
craniofacial morphogenesis and/or palatogenesis, may contribute to the 
incidence of OC. 
4.1.  Our data provide additional confirmation for the role of MSX1 and 
MTHFR in the etiology of nonsyndromic CL/P in the Estonian sample.  
 4.2 We found new supportive evidence that the orofacial clefting locus, 
OFC3 on Chr 19q13, is probably involved in nonsyndromic CL/P 
across different populations. 
4.3.  This study provides, for the first time, evidence of the implication of 
IRF6, COL2A1, COL11A2 and WNT3 in the occurrence of nonsynd-
romic CP in north-eastern European populations (Estonians, Latvians, 
Lithuanians). 
4.4. We could not demonstrate convincing evidence of an association 
between CL/P and IRF6, the candidate gene most consistently repli-
cated. This result could be explained by the various confounding factors 
and heterogeneity among the populations. 
4.5. The present study is the first to demonstrate an association between 
CL/P and common SNPs and haplotypes in FGF1, and provides new 
evidence that variation in the TIMP2 and WNT9B genes contributes to 
nonsyndromic CL/P.  
4.6. We have successfully replicated previous findings implicating FOXE1 
as a susceptibility locus for CL/P across different populations. 
 4.7 The results of this study underline the importance of the FGF and 
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SUMMARY IN ESTONIAN 
Mittesündroomse huule- ja  
suulaelõhe geneetilise etioloogia uuring. 
Huule- ja/või suulaelõhe on üks sagedasemaid kaasasündinud väärarenguid, 
esinemissagedusega 1/700 elussünni kohta, sõltuvalt geograafilistest ja etnilis-
test variatsioonidest. Huule- ja suulalelõhede kliinilisi klassifikatsioone on 
erinevaid kuid üldiselt jaotatakse lõhed kaheks suureks haigusfenotüübiks: 
huule ja/või suulalelõhe (CL/P) ja suulaelõhe (CP). Suulõhede tekkes mängivad 
olulist rolli keskonna- ja geneetilised tegurid ning elustiiliga seotud riski-
faktorid. Sündroomsete suulõhedega seostatud geenide uuringud on näidanud 
nende olulisust ka mittesündroomsete suulõhede etioloogias. Geneetiliste tegu-
rite olulisus mittesündroomse suulõhe tekkes on kinnitust leidnud perekondade 
ja kaksikute uuringutes. Kandidaatgeenide uurimisel põhinevad assotsiatsiooni-
uuringute ja aheldusanalüüside tulemused erinevates populatsioonides on va-
rieeruvad ja vähene kokkulangevus on põhjustatud geneetilisest heterogeen-
susest ja väikesest uuringute võimsusest. 
Suulõhega sündinud lapsed vajavad ravi erinevate spetsialistide poolt ja seda 
erinevates vanuseperioodided sünnist kuni täiskasvanuks saamiseni ning tihti ka 
kauem. Suulõhe diagnoos ei ole eluohtlik, kuid neil lastel on kahjustatud paljud 
olulised funktsioonid nagu: imemine, kõne, keskkõrva ventilatsioon, kuulmine, 
hingamine ning häirunud on ka näo- ja lõualuude süsteemi areng ning kasv. 
Need probleemid omakorda võivad põhjustada emotsionaalset stressi, psühho-
loogilisi probleeme ning võivad mõjutada lapse hakkama saamist koolis. 
Rehabilitatsioon on võimalik hea meeskonnatööga erinevate spetsialistide vahel 
ning heas koostöös lapse perekonnaga. Pikka aega kestev ravi on ühiskonnale 
ka kulukas. 
Kuna mittesündroomsete suulõhede etioloogia on multifaktoriaalne, siis 
väga tihti on raske leida tekkepõhjust, ometi ennetustöö ja inimeste teadlikuse 
tõstmine võib vähendada lõhega sündinud laste arvu. Suulõhede riskifaktorite 
teadvustamine ja kaardistamine on esimene samm ennetustöös. Genotüübi ja 
fenotüübi uuringud võivad tuua uusi teadmisi lähiajal, aga selleks on vaja suuri 
mitmete keskuste koostöös toimuvaid uuringuid, mis leiaksid seoseid nii 
keskonnategurite kui ka geneetiliste riskifaktorite vahel. 
Eestis puudub riiklik statistika suulõhedega laste sündivuse osas. Huule- 
ja/või suulaelõhede esmased lõikused tehakse kahes Eesti suurimas haiglas: SA 
Tartu Ülikooli Kliinikumis ja Põhja-Eesti Regionaalhaiglas. Juhul kui suulõhe-
ga lapse vanemad otsustavad pöörduda mujale (välisriiki), siis ei ole võimalik 
juhtu dokumenteerida. 
Käesoleva doktoritöö eesmärgiks oli:  
 Ülevaate saamine SA Tartu Üliooli Kliinikumis ravitud suulõhedest aja-
vahemikul 1910–2000 haiguslugudele tuginedes. 
 Erinevate lõhetüüpide esinemise suhte määramine soost lähtuvalt. 
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 Huule- ja suulaelõhede teket põhjustavate epidemioloogiliste tegurite ja 
nende esinemise seaduspärasuste leidmine. 
 Ananlüüsida kraniofatsiaalses morfogeneesis ja/või patogeneesis osalevate 
kandidaatgeenide võimalikku seost mittesündroomse CL/P ja CP Eesti ja 
Kirde-Euroopa (Eesti, Läti, Leedu) uuringurühmas. 
Valitud geenidega teostati ühenukleotiidse polümorfismi (SNP) case-control 
assotsiatsioonanalüüsid nii Eesti uuringurühmas kui ka Eesti, Läti ja Leedu 
ühendatud Kirde-Euroopa uuringurühmas eraldi CL/P ja CP fenotüübiga 
patsientidel. 
 
Uurimistöö olulisemad tulemused võib kokku võtta järgmiselt: 
 Üle pika aja on antud uurimustöö esimene, mille käigus püüdsime saada 
ülevaate 90 aasta jooksul (1910–2000) Tartu Ülikooli Stomatoloogia kliini-
kus ravil olnud suulõhedega patsientidest. Säilinud oli 583 dispanseerset 
kaarti (251 naist ja 332 meest). 
 Viiesaja kaheksakümmne kolmest patsiendist 19% esines CL, 39% CP ja 
42% CLP. Leidsime suure isoleeritud suulaelõhede esinemissageduse (CL : 
CLP : CP – 1 : 2 : 2), mis on sarnane Soomes ja Rootsis tehtud uuringutega 
ja mille põhjused vajavad edaspidist uurimist. Poistel esines sagedamini CLP 
ja tüdrukutel CP. Vasak näopool oli kahjustatud 2.2 korda sagedamini kui 
parem pool. 
 Üle 1/3 emadest kurtsid psühholoogilist stressi raseduse ajal, 45% emadest 
olid teinud vähemalt ühe meditsiinilise abordi, 1/5 emadest olid kokku 
puutunud treatogeensete või toksiliste ainetega. Suulõhedega laste sünnikaal 
ei erinenud tervete laste keskmisest sünnikaalust. 
 Uurimustöö tulemused näitavad et paljud kraniofatsiaalse morfogeneesi 
ja/või palatogeneesiga seostatud geenid, osalevad suulõhede kujunemisel. 
o MSX1 ja MTHFR geenide järjestuse variandid on seotud mittesündroom-
se CL/P geneetilise eelsoodumusega Eesti populatsioonis. 
o Leidsime tõendeid, et OFC3 lookus, kromosoomil 19q13 on tõenäoliselt 
seotud mittesündroomse CL/Pga. 
o IRF6, COL2A1, COL11A2 and WNT3 geenide järjestuse variandid on 
seotud mittesündroomse CP geneetilise eelsoodumusega Kirde-Euroopa 
pupulatsioonis (Eesti, Läti, Leedu). 
o Antud uuringus ei leidnud kinnitust kirjanduses erinevates populat-
sioonides kõige rohkem mainitud ja CL/Pga kandidaatgeenina seostatud 
IRF6 geenide järjestuse variantide seos CL/Pga Eesti populatsioonis. 
Antud leidu võib seletada geneetilise heterogeensusega. 
o Antud uuring on esimene, kus me näitasime, et FGF1 geeni järjestuse 
variandid on seotud mittesündroomse CL/P geneetilise eelsoodumusega; 
ning leidsime kinnitust et TIMP2 ja WNT9B geenide järjestuse variandid 
on seotud CL/P geneetilise eelsoodumusega Kirde-Eesti populatsioonis. 
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o Antud uuringu käigus leidsime kinnitust, et teiste populatsioonide uurin-
gutest leitud FOXE1 geenide järjestuse variandid on seotud CL/P genee-
tilse eelsoodumusega Kirde-Euroopa pupulatsioonis (Eesti, Läti, Leedu). 
o FGF ja Wnt signaalrajad ning nendes osalevad geenid omavad olulist 
rolli nii CL/P kui ka CP etioloogias. 
Mittesündroomse suulõhe etioloogia kätkeb endas palju erinevaid tegureid ning 
nende tegurite ja tegurite omavahelise koostoime uurimisega tegeletakse maa-
ilmas. Uuringute teostamise teeb raskeks huulelõhede multifaktoriaalne taust ja 
ka erinevate populatsioonide heterogeensus. Uuringud on näidanud erinevate 
kandidaatgeenide olulisust erinevates populatsioonides. Vajalik on erinevate 
regioonide detailne geneetiline kaardistamine haigusseoseliste variantide 
funktsionaalsete effektide kindlakstegemiseks rahvusvahelises koostöös erine-
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